var title_f4_3_4144="Uterine septum PI";
var content_f4_3_4144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septate uterus: Partial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 5th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4144=[""].join("\n");
var outline_f4_3_4144=null;
var title_f4_3_4145="Dermatitis zinc defic";
var content_f4_3_4145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Dermatitis in zinc deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perianal dermatitis in a child with zinc deficiency, which developed because of total parenteral nutrition with insufficient zinc supplementation. The second panel shows dramatic improvement in the dermatitis after only seven days of systemic zinc supplementation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Klish, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4145=[""].join("\n");
var outline_f4_3_4145=null;
var title_f4_3_4146="The SynCardia Total Artificial Heart";
var content_f4_3_4146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The SynCardia Total Artificial Heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy: syncardia.com. Reproduced with permission. Copyright &copy; 2013 SynCardia Systems, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4146=[""].join("\n");
var outline_f4_3_4146=null;
var title_f4_3_4147="Asteatotic eczema";
var content_f4_3_4147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Asteatotic eczema (eczema craquele)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4147=[""].join("\n");
var outline_f4_3_4147=null;
var title_f4_3_4148="Totally dystrophic onychomycosis";
var content_f4_3_4148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Totally dystrophic onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFfAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDG8zA4prt1zWf5w4xj86mjfex55rzT6OUrI0rc0zUF2xMvrU9mvyYOOlLeQq4PY4711RWhwVJanBaupLsKw2PPP0rqdWtQdxHXvXPXCFGx6VnyiT2L2mOQQBXSWbfIueRXJ6c+JRk4PtXT2snCk89KwlozuhPQ10l8sYPQ0wzAyA55qrNMNuAOetNXO7pS6WNkzobPb5YY/kKvW85zgHjvmse2m2xqO+Oav2z/ACjA5NNGc+5ps4ZDg5Pf29qZFIQcKMU1EAXIb8KkxsG7jir5WZOVi1Buc8j5cVNLGq4Ib6c1SF8iRnn5gKzptSZwQoI/WrbSISbehfvroovBBPqKy5b9yxU85/nTNryDc7E56ipIoBj5Rk1m5NmyaQRIGJYjBParUNu244AHvQkQ45xViGPcQAxHrxSsjORLsCRkZy2ORRFGrEhSRzyKYy7pcdcUgLCTaTgHrRcjlbLg/d7gORnjNO3AKeimqbyiDI4Zs5z60kk7zHcw4HbmqTGoXLaz4+8RnGDxTVvASVXHFRRSR7cSDBNLIkO8Y+8elJrQaiTLO6fNvyPTPSpDNGIgeNxNMRFfABA+tD26pJ5gZSoHrU7DXawGRZFJ4DA55qN2IAKseahncPJzjHT6VC0uzn5iAaFYtQLS3DIf3h4pzsnl7w24/WqW8ynG0keuKesnlMAFY8+nFNlOKLaXCn7ynmn+ZEcbuPaoLiZGKCPAPvTJFdwSSOPShaEcoZQvhGBFDRlH3ggjvTJEHXnPoKZiVSSCSPene4yS65QMnfriqcJD53MOKcbhz8rjj2FKrRnheCe1KxdtBjHbKAhPtilllkB6Aj9aVwwOVGB69aFJZzuHOKNiGxcCQb1IzUIYxHf3z07VKUKMSuMDtSKBMxPU+hFA7lfC3DtuOWFV8PBNk5FWpY9j5UHd64pwImG2QYYd6Bp3E3eeCwA3YpiyiMYJxinJGYXyR8vf3qS6iDpujGeOwqbBdIoSpuYlOlVmUnknBz0q7FxkNnj1qtMpJyPWgtFeVyACOB6VWfLupbNWmXsajYAd6E+4mtCuTubBGR60yXHIJqYAK3A49KiuVJ6YGTVGDRDJxFwOeaxbgYkyK2iMoM9az5oQx569uK0TMZI57Uow0DA9+lcFfJ5dw644r0m9yqNx9K4LW4SlwWJHPauui9bHn149TK2nNAPOKX8DSjiupHKNKnNFOopgexLMTjnmr9uSCOM5681k2PzOOnJrct0+UDj0ryowPdnUL9tcbfp60l3e7dxLDjpzVWX5BgHr09qyr2Q7Wy1ap2MWrkWpXqyFsHHPr1rn7iQM7Y6etWLpyxPPQ1QnbJPI60lrczlZEtq4SQZ6V0tnMohH+NclG/7zg1tWUx2Dnt3rCasdNGd0bayZcY5q6r5IA7Vm2jM3piraE+YAvP0qEjpuacYG5eT+dbFlkqOMAcZNZ1mhYK23J71teasUS4ADD0q4x6sylJvQmlXEWWYAZ496pXF0xj2p1NRm4knY5bB+tEKlmOPzq79hJaakShyATx61Zt7QBN2aeVCLggGpIptu1dpx34rNod2yKO3O8jJFWUj2t8pye9PchzgDHFLHFtOM456+tIF5j0j2/eJGaa+9MEHC9M+tSmUZ4OdtJIVK4J2oadiblY7lVmZiOwqEMzuNzEDvVqcIseVO5gelMjGWB2nJ/ShK5SelyVHVyoZRnrkCpBCfM5z7Ypqxyq4wMAd/WpNhUg7hxx1oasN67CFVJ5GMVIEUuuOQe4qATIHwdx7E1NuZSCh4PWkVyMmkiAbgnP5VXnhkwWPyr6CnvkjJYknkcUCVmGyRS3vila5NnuZzof4TkfyqeFXMeThgPWrot4GG4sAfQ01Y0VsKQVPcHpVchXtL7CQhchU445qw1izRFsgrjjFNeIZw0igevemGRoQFjkJx2qdtzO7ZH9lVkPAyKYEZACmSB29akM5eYb8c9xVkQBxy46du1G+xd+XcgjeNsBV+Y0T4iJBHT0qcWSLl9wx1pRIinEo3jsRzQiHJPYplbcgcbT0waqzxRpyq5OeDWjcxo65iIIB9apKGTORkVVxp9yt9odUIVSyk5PHSnko8e5Dhj2p8boSVK4OelNNscllJBznFIdxixurAyBtp75qS6gMO1ojwe9NZpCnl7sjvxTRK/wDq5T8tDKSYyNyw+bOabNARhw/5U6SJxyoytQEuRjJ+lTdlLyJA6vhep/lTkl+zP+8BKg8VApaPJAPXrjrRNcbo/nHbHSjXcdrj7uNHUyIcZ61WjC4GetJBPtOGJIPY8Uk67Wypz9KaLSsQSkHrgVDIm3k81OyrImDwwqFWOCr9fegCN154qGRSw+apiDnpTZASeBTMpIoSttPHXpVJ2xnJ69BWjPGwOSOoqjJHz1GR0NHUyexk3yAru7HtXH6/FuUuMDB5rvZYS6MCfwArmtbtNyOAAT1rrp3OGvG6OFVvXpQV5p8qlJSpGMGkrtR5wzbRT6KdgPTLOcBwQa3La5BQZPB5rlIpwq9etWo9QULgtgD0rgUbHqc6e50ss6kA7qxb+dTu5J/Gs+bVM98fU1m3mpKFY7uKu19DOVRFi5mwCKzZ7gf3hVG41LcMDJB71myTkt1NUqZzyq32Ohtpd75BBrYs5MlfYGuY0x2dweTW9avg+lY1InTh6jOjgl2x8Nye3pWlY5aYHdkVz0Upx3HtXQaUTw/J6VzHcm7HUWh2qCO4xU1x8xByMVTtpQBlgcVOQJZBtbitbiXcOABgfWrFuNijbjBqGQHcuAfyqQy+WuFzk+gpDfkOkcsSB171IGcrt25Y8UtvgJuYHJFSxtzu20pIolhi2R7mOT/Wkkf5N2fwFRlyUckn2qrLIZCM9vWoQkupatZTGdzAn684qR382QFwR7VTDKi4Bye+alaQE55AUVpawnqxxZVkJPPYZNWInJwVGM+1QQsCQWU/iOtX3k2RhQAMjjI6VK0DbQrhmZlEjFVB6jpU08ce3cHJBqq5GBklqAZJCFCnb3pSd2XYseVCVL7uR29qVMCQh87TSQI6nYQOeDn0qctbqpUlt3pjipB3RIWjjwoTIxwaljETISxLEDoO1VUuY8bSpwOlPt2h3cyAA/pVLclrQVhzzHvT2qu6hgfKBHsaum32uWDll9BSRdGVUyPYc1TVxJlSKCUHDnd9D1pr5ywCMo71ZEUol3qVXA4zmm3T/Lud8nvScdBp3Y2zjDoc7cr0qWEokuxuAepzVW2Zd+dxz61OXyGLjj9agHuXpDABgHcOxFV8wkqR0PNQW8vkHLDK9OlTbf8AlogG00yLWK88ohP7rr6VD54bB454NTSMsshV1xn9ahliRB1zigpWGXECj54ySD6Ukc6PHskypHGSetPt51RwrAmM9RSXduivuXPlk5FNWsOOm5SA2uTu3UrMHBIHOOaiaRY2bBzUsfzLlV9zUM3sTGQ7AwIweCKrTKM7lPHpUkYXoR29KilABI5p3FFK4MxaLHQCmQ4kjdT+FNOwdT+lRsxzlM4ovoVy2GNEAcNwR60ingox6c07eJCRnmo8c4Oc+tSaCbSHzn3pJlVgXAGaCd3HNNUheOuewpiGICRg4pzrkZHSo2Qg5JxUqEEEdcVS13M2VpEGeuaz54/bvWhPgdDVGfoKb3MZFIrgMB3rE1KLeD1FbZIBFUb1A0Qwea3g7HLVieaarEY7p8DAPNUq3vEkQWRTn1zWAOld0HzI8qas7C0UUVViS4b+T+9n6UNfyHgEiqdFLlRTkyw93Kw++aiaR279ajxS00kS22GW9aBnPNFHfFFgNrRwMVsRZVhWTo3KnFbCnHWuOotWdtLRXL0MnIAFdXpP+pBI5rkLIAyr3ArtrFcQpjvzXO1qd0HdGmrBYwT6VJFnBIznqKgkIKgAdqljO1M5z9KDRF1ZuMDljT8qQB3z0qjB+8kyvHvWjbICMkZxxmgdidE+XkHgVMxi8k7Tz3pjS/uiMAE+9Qqw2kMwFJy6Ba5EzcbcnGfWonlDyhVA4qVBExIZhx7dahJJf92g29jSiXoWrdA4G/H5dKJVRHHzA/SpLV1VSuGzU0YTfkrn61TaJXcI2WNFZiHP93FLIRM4Yt05waV8yudgXA6VBc5VuWBb2qbjjZk7kFcxxHA6kHNK1x8pC/Kc8gVmwSPuZYycHqM0kzyeanykDPNTc1ULmqzq6ruJ3dCc8mkuGVWG054zk1Skn2gCMk+54pDP1BJyDnNIap9SRp4y2WznpwajcncHiJfuVHJApC8Ey5dgMdcDrSxTRxS/JllAwMUPbQqyWyLVvqMsQwAWHvUg1SVJd8QAPUg1kPMUYsmVznOaPMk4bcGX2o5mtCnTi9bG+NXMzYuIVI67lHSmSxpdKWt3OPRqo29w7RPgRgY6mq0OoPtMasMDpxWvNpqZeySfuovxbo3KnAxVpJEeMkuM1kJdSxy5LBvXPQ1cjkgZvnzG59DxWfXQJQtuTGVGGHfBHvUsEiqPkcNH3HpWfcQsrHYpK9sjqKbGiOhKMyN0PNGxLppo0ZIywJj+729arybyCBgY7etVoJ7iIkM2R0waJrieMKSoK4647UNkqGo5t2cmpLScZMdx0I4JqKK9haMCVCDUDskjEI3vihM0celiae2KsSw49aYpMY4H1qxbFpEKPy2OOc1G58ttjAbunNAR7Dok87I6MOme9VpPvsD26/WpA78FTjHWmzDcuQfmJ5FJ6oajZ6lclN3PNEnT2qEBmfA4qdQccioNbIi2bcMvSkI6kDj3qQHDjdgKameMLyrcnjBq7CbRVC8ZxzSPEeoGKlD5OCMYqUocdaViG7FFkO3BpoyFPerToe/NQOuw44q1uS7Mz5iVbr19aqzg4x29auzJubpniq8p+UgjAp8pnK2xkS9MHk+lN8hih3DJbj6VPIuGB70SNxwMj1rWmctU4nxPakRsRzjrXH9Pw4r0fXIg8TjbzivPbhdkzA9q7aWmh5dVWlciooorUyuFFIetLQAUUUUAFIeDmloFAGto0u1gOa3QSQPSuZ019so/SukBO0c9u1ctTc6qMtLF6wGW689K7TTXxABntiuQsFyFA4NdPYNiLnIOK5JOx6FPY1v4So6UJN8uwDJ6ZFV0chML3FS2UTFyRxk96jdm6NS0jBVcnnFaEBGwDt6VWtIcNgntVwjYWZuR7VTdhXILkAvhcgD9arZCgkkE1JO2fmBxmqcshCMAP/rVCL6AZOcA4Gc1ctZVTapGR1rIyc7mHOauWu4bSrd+M1qkQ2zaBRtxXKc06ZhEqEnr1HQ1Ba4Zxk4UDP1qCe5EkxJ7cAmpkuole9i2PLLZDkHrxVOSbLMARlc1HLKc5U7ai2NIpznJqDaEe5NDMrcH5CT1q+LZyAyuG7kqc1nJGAu1h04zVy0EsLZjcoD2x1px7FSdtUR30UrRKQfkOPY1FbaZcXJJGxVXuzVpOxeQMwHy9TjBNWxEl0CigRHH/fVWoJsXtZRRhXVsAfJjVnfPLL/9amvA6R45BHGQK3YrOaFSkIIb1A6VG6zu+LiLeF6/LQ6Y1iOhgPEUIBZseh5qRfQLj2rc/s8TAFAEX1P8qLnSmjiGE4H905zU+ye5arxZjhRI3y/IwHIPeliVEdvMwuP9nmrUdt8hLKE579aiuVEYIwWB6NSs0Ny5tCuoBYrhSp4680oVo5cMcnHHeocOZQFOcnkYq8wAIBOGXpUouWg+zuXZfKkYImfvd6r3iNFlt5IB4IHWluDH5WHIPOeOo/CkivnkUQDGcbVJFWrPQzkuqKUkpdwRI27+dXbW5zCY3Ib0BrLnUrIQeHB6VGJniUgAA+tQ3ZjUVJF5nTLKwwagnjkXa6E49R0qbcLmOOTOMdauWkqxq0MgBjb71KKTdgleK0MmO4kRtyuwP1rQgv1cATrkj+L1pz6eocmL5o+oI5qk0TJkYwKLNMtOMtDUCMyhoyCD2xUKjZIN3fg1X+0NEqmNirdDVqCbzivmDDd6pCaaJZbbC7k+6aYExxnB9O1X4AzKUByCDz1qhPE6nOeh60NIzTu7MgkG08jrxUaSHdjr71YLo64c/MDxTMKPQHoRQVfTYgLfvSGGBVyI70OR0FV5AGHAyalTKJnoTQTJaDZGPsBmoJFBHHWpX65zULcnqfekRYjZOoArOuk2E5zitaUgxbV/Osy5XcuCfatbkNXMmRh94YzVaaTAKqcZOTVm9jw52c9uKpOrcbjjFVGVmY1ErFa9AeN84Ga8+1yLy7onoa9EuQ2znnIrj/EduDh8dK66b1ueZWic2OlFISAcZorexyXF70UUUxhRRRQAUUUUCLFicODmultzlFyPSuYtThsZxXSWh3RL61zVTooy1Oq0BELjdt4FbErCKReOCKydEUKobjgfnWldsXwSO9clTY9Omi5blmIA5B5rXsoiAN1ZdipKpjP1FbgAWMDvjrWafU2XYtBckBenfFO+ZyVzn2qtHKVUkZ60xJyNxDY9aG7l8mg+4wuA3BqnIAykr19aJZGkkxnd+NX7RUjRtyKQRySelEGOV4oyypUhm79BVyyimuW2RRde9LtEkoSPjH61p6REVuVjeQlm4wDgitYtMykrXI57WWOFEKMHPXmpIdNlVFO1Se4Jpl8Ha/ZUmJjQ4H9atLDbpjzHdpD2HT8aV9QSaSJ5NKZbEu6RYBxndzioJdPRdhjmTp0z3qO4VpFI2OIj2zwKqpatMTtXI9M0pNX0Q4LuzYi083TKCUYnqw6D61s2Ol20B3PGs+OOtYEOl3FvF5sspgUfdHc1DDFdzSuQ0iRj+I1a06ClHm2lodPdadYMWbd5ZHUM3FLD/Zlux3zREADjOQa5saczviSRpCRnOeKvrpMUZQPiWPvt6g+1VzN7IzcY2s5Gub6xklzFLGEx9wkmr9pd2axbQ8AJ6sx6VjPpe61Bs9oBHJHUVRbTRb7v3ivKBkqRzVOUl0JUIS6m5d/ZJ1I863yvffjJqCC7gClN9uD67qzY9IiuSWjiKADO5TkfkabLoihdzzrJjosfX8anmn2LjGGzZdupLV5FwkJAyG5+99Kzri1gKlQNvOfvZxWfc6e5UsgXbnqpyQfeqsttLbBfNDAv096zc31R0wgukjTksIovvOvmAZ+WlFquxtzruPUisQRyuSCWU4x17UyVJVJIdsDqM1HMuxtyN9S5eWMQbMcoLA8+9Uza7gQmAwOQ2arOrbcbmH41UuLadSCsjDI9afMn0L5bLc2isU0ZSchblRwwGd1ZMsG2QZIz6dqqBJPMOGbHqTVuyuimY7lfNjJ5J4x9KmbvuEYct2LbsYHJDAhu1XmK7Aykc1WmtIJsyWMp90Y8j2pkaMq4ORio5WhWvqbGkXXk3AV8GM8HPNP1CJVbBGATkGsdTtzjJxWrZ6gZoxbXOCuPlY9qtS0syXCz5kUvIjBG9wOelP8AlJBi4YnGKS5jKSlW9cg+opsYw+M8ZqWi/NMv21w8L8jPGMUTTLISQCp7g1GcRk5w2elRAuRgAn0NN3Mra3I5E5D+/apkjEke5cAg85pCrAgtwPrTd2xjzwaSdxkkShDkgGpJIyxyoz7UoVGg3qct3BqOOQjANMj1IZwEbBGKqlSOc8VfvFDKCRj61TVWCt3AFD3sVbQgJPQHFRPgx8//AK6e4wTjJ4qNjxVR3IkrGZcDnkGs26DfMF5GODjtW7PtKfN19KzLtFIwBkY7Volqc0mUJdqwndnkda57W4g0LcZ966y5t1FuT93isLULcGH146muiJxVbHnMq7ZGGB1oq3fw7LpwOmaK6NTz2ynRRRVgFFFFABRRRQA6LO8ZrodIbcAv4VzqHmtvQ2yyjrWNZaGlL4jubA7I1wRz6Vox5lOTmsqzYlFAODitqwhJYA9a86T6HtQWho6apRgM9603YggHvVdIhEoPXjNL5uSAc5/lUmsFrcnzkYzznNRAr5hXkk/lSs2OQMnuaIEJbPVvSpNUiS3gBmCgHcewq/HB5bhZc/NxgVNo4BuUztX+9mprlo21CWW2k3hBj8atR0uZOV5co5LK1RBJJKqkHOwDkU+1vLOzDMLdnlJO2Q88U3+zLlrVZuS0rZCjBIpBbrBGQ6ubs8KuOAK0u1sjNxi92RywPKm6PK7mzgHmq7xESCMOX7nmujikbT7EKseblxjkZGPf0qta6dIzKw+8xyMDHFRJXehUaiV77EFpbq8aqC7MRyFHStOH7Jp6f6VbF3Iyvr+Iq7Cot0WLyme4zwBwauf2LM8nnXqDzyQcGTJA+lbRjZHPOopfFscp59zcyFsHgjardq11kl6XSNCGGQIxkY9MV0sGkh3OFV2z1IwAKla0tVcZYAKuMKc5NNQa3ZEq0XsjHSyRFDRSrIGGcEbWJ9KpTh1Y+fEYFbpjmunh0yJd5W2eVeu7POasPZKUAMXlt2BO6rijNVUnrscdEGKj7MwPOGJGBWpZzRyRgCFfO5DStjH1rSvbG3HltcQxALwSGxkfSqs9rZRIrqku1umxs5qrND509jOkhZSQ8m6ccrEvAcVnyi4kkb7LG9vIvzMD/jW1aabDdfOl0VcH5PM4Ye59qfPZyISrBZQBgsCTScbmiqKJzuwzTeXcqEkbqx4DfWlmceUbNiGjByknXB9jVu6jWOM4TIIwd3P5VmGJ3IdIyo7Hsf8ACs2raHRGSkVZdPYOJPvBu545qldW65JUtkdf8K2Ve6gBDJ5sZHKkZH/1qRpdzqGh2qB6dPas7LoaqctznDCWUdGHcelVyCTsIBB4z6V032ZWTeFOeRwaozwFAAVwOuahwaNoVU9GYE0Kg4X88VEqckcfWtW4h3r7Z5qP7MsWGxuU9qh3Nk7GT5ZRmKHDY4Iq3a3KtHsuVYkfx1LNGCBtT8aZ5BZTvG1vWhSYNJlwWsc0bOrqOOMd6qNDKq5x9CKiRJEyEOMcGpxNPsGW3Aeoptpk7Im87zYBCw3SL0aoVXGDznFLFOElDuuDnJxVid4pHJQ7c84/pSM72dkRQyh9yFiD2p8MsiZORxxiqbxuzDZ26YrStYy6bgCzD72BTSuOVrEbjPLn86rzqBypFX2Ub8beKjaJN2XGB2osQnroVrdnGB6VbMqBDhRmocLuG1gKa6qHyDwe1K9hv3ty6Ak8W3cu6qVzAY14I/xpLeUI+QcCnTuWJPHNW3dE6plB2+UiqcrFBuz3q+6Aiqd2hKn5eKSBvoULqTdGcd+MiqSh3BAx14Jq9AoLFXXIFTG3BG5c4zWsFfU5qlolPBKlX6YrH1rb5eEA+gropEBjOeG7VgahDiQtyMe3Wt9jiktTgdSgP2puO1Fbt1aq8pZl5Ioq9e5zOkmcRTSfmA7GnUV0nOFFFHfAoAKCcUhyDjHNPxS1ARAcZre8OpukPp61hgjIBrp/DkJEYyODWVfSJth1eaOr08I0qBuOnNdPbRRxlWRs1zlhGu8EnGBxXQ2hwoBwOK81M9lRLMjsDgU3cxIJxn6U18eZyMnHFSkqhA60mbxRLAWIJNWIiditjK5qKF0ALFePfvSyTCZ8Bdq+goLS1HzzHcQg59qsWCNsCphAeTnj86rQoHUAcv6Vu6fpFw8IuCFEe7GSeKUU29Am4xVy1azo0IhidyVBJYdB9K0IlnWNbma4CnoobrTtLsYllk342Yy6j5an5u7xI4gURRtUvyAK3S01OKUlfQitre9Lu4HmBvmYhcjFaQN20cTz/KuMIi9T+VaFpHHaq7RSM0YHfpn6elIrrOI5MFTnDAHgn2NVGBg6ncfpiCNXbhpv75OW+lXRL9nbCqPNYckjpmtbTdDtJU3rOwL8nB7nsKlFlbCd7aG3YtHjfK56+lbxptI5JV03sczI0i3SJKHdyTtYcClvCliNsg/eOcqF71p63LDpmRdXcMOOUDDJJrl7jUNHkk82V7u7dhwyDAz6Ck0l6lwk5200JW1+KIbG+7n5gpJOah/tn7Vd7LV5kyMAsxrAnnkd3NrZ+SgOCzHk++KSKG7QqEfbu6mMcgVl7R3sdPs4pXOjOnXU4aVjJgccnrWfc2d8jMsFvJ3O/PBqbTY72CQrFcShBzhnxWxbSy/6173zN3VR0/Gqtcy53HszmRa6ntOYW54I9agmm1C2G3dNEw4GScAV0xl+dl+2qA394nj6Uw3ThdpuoZHB4EgJFS4ruzT2zvqjlJ7u5fAeVxnjBFEdxOsTRxSEgcnjpXVhoblHx5UU5/iGCpP0rIeK6SUgwRseuVA+as3BrW5pGqpK1rGdHeX2UOVIx3GOPQ0x7263eW67ccg45/8A1VbYI7kztIhx0FQzBkRjDMjFenGDUPmT3NYyT6EUbuyj9yv++rY/CpZo2deYzhhxxnBqq00u191p8rj756g+xq7pX2eUKkN/LaXB4ZZuVJ/pVp32HJyjqUzbAjBTJ/2arfZmTd8uV9BWzeWV3YxefdgNGxxvjPH1zVKOUIRu2sr9DnkGhx1sy4VW1dGe9thAwVj2PHA+vvUaKgTbJHkAda10u8OQUwuQCe1HkrLc4iKuAc46Cm6ZaqvZmH5GZMLwrVN9mURlW/hq1dW8gkZtmw56elR4cdQc9/esuW2hTk2ih9nJYgcfUVBLAxByRnPWtJkdlYgEqOmetQSRiJi5JyOxp8pKmygnmRfNnHpWppWpfZ0l3Dl/Sqc5UnPVc9DTo4wysc/lSu0y21JamgHjkjyrgk5qOaMlCxBAxVJIXJODVh528jbuOVHp1pasNOhEzqqldoOfWoptqxDOeetKJw33htY1IU85QVAJHvQN73K0Zjzy30rRghiljyOT3qqLdWUbQQy9RT7dghf2qo36kz97Yr3MJjk29B2NR3kSqgO7Jq0f3wbP3hVS4QlAe3vV7C9THcFWwvSpIy+CQenY9DU0kW0c52moUX5Sq1cFY56pCSSmSKxL+Zm4xgDpW/Iwjt2GdxP61jyoDBJIJYwVcL5R+8c9x7Vb1ZytI5+WMs5JFFX5YzvOBn6UVfzMNDy+jNB6UijdnNdZxC9elOUbc470AY6GnAZ68UANPzEUpz6U4Ag4WnEA9qAGxJvmUDrXd6HCqRopxjA5rk9Hg8y6U9cd67a0ARVA69hXHiZX0O7Bwu+Y3IIYwRsINaUAZQDnIHas6zQsUZs57DFaW7BOK43uepBEpcZ3HJNPRdybmPPYVXUhhjJ5qxGcEKRkjpSN0ThdwC+tWliREH3cntUEL4cdj71pQWzzKjKoHPU9Kl66Iq3cbp8IadVJ2rnqBXTt5sDR2kUwdR8xLcCs/SLQT3DQoMyj5s54rXgijQyTSl9xPfpWkE4nPWkm7EzxuZFic5Yj5sdxWnHIIkUShFiTkjHJNQacibDcIC0aDMjHv7VHfypuEsKlkJ4A55rZKyOOcruxamuHnUO2RETkquBxVuK0kluEWBAsWDh5htA/CorKa2s7Nbu5w20/dYZAJ9RVDxF4wj3Kba4jkGOOMD8q0uoq7OduU5WgjubG3e0iV2uml8vgMOFUUy71eytzK1vGrB0G529q8rbxbezRPHJcuyDkKDtGf61Sk1wuFEiFl7qehpe3S2JWEm3eR2OrX+n6vLEbm0DBSV8xFPT6ntVJTpdk8WTiPdgIP4feuWbVZnVQuI0U4C44NEFy0tygZxgcnjFZOsm7m/sGo26HX+IHsoITcW1yHXIGxV5Of6VmR6qhgZo0YMvKlxWLDe+XcTuzExlCpwcCqiSAFh5mVPI+Y0Tqtu6KhQSWupvrqbtuMr8jpgU+bUf3cYjlUYG4+uaw0QsfkJcqCxx049aW0gecFskAAk57VmpSNHTje50O5vIDMyHf8w5JK1X8555HTegOfvk4IqlBcLbnCFmBXd8wxVC6lUFmXOSfu460c7uCgba3QDNh8qvXIq7FfF4cKoVB1JHT6VyTXgiiZAu527g06C/mz8m5F9Cev4VSqLoEqdzsoTFcwsAgkwQCTwao3thLGMrG4HOWByAPeqceoxWyfuNpMgAcEc5rU0XWYpXlVx5cSqc5b0q7RlozB80dY7GMsdxKSqSovPG5sVFPbyrO32iMsW/iU5GPrXQPdaVfzKg+R3PXpg+pNWrK0tDK48yVo0IBKkYHvQqKexft3FaoxBCxtGitbpsH70LnAx/jWa0CR43Bo3U885Wuu1Owso5FcyJKrcgfddaypLGONS0btKhONrfeX3HrSdJp2HDELqZcNxHJKEWUpv4PGfxqw9vPay7lxLHjJdaihe0ivpJHjMgXI2ng5qVb6UOTlhFjnPf2oT7mrm1rHYkIV42VkbI53Bs8e9UriPYrEO23ruHatITW5RfMxC7dD61JHHJsCna2fTqae71HGroYSySqF3Llcd6b5m6Ijywcn8RVvUbZ4pCVSRYx94MOlRERCJiGIcEZ4pNam2kkmjPkQFxuXHrimhliygDFj/KpZQzSMBgj1HNIkLuSVOWUfiKhxuXYYJmZvlIXI6VYSVHToA2Mc96oxowc7k49e9SEbSDjJ7Ckr7BJWegySI76cqmJskkA9MVYIDoDt5zyQaS4RZVIVmyO1NQswU+hEksnzFcnNRRzMrFX6Me9ClwhAz7mjyCyBj1zVFbEiyBZE+YhSeatX9pGAr7xhh+X0qC1g80mN8FhV9rYTWxRiQy9/StowujCpKzVmZmp2QfTvMjPIGcelc/Zq0jHseua6wKI9OkjPHXv1rnIIWViyGhqzTMU9HcdBCz2GomKAXFypVAuMlEPVwO5yB9Ko3do39g+Zc2qwTRzLHDIVKtKpyWBHfHHNasEVulvPfXMlzGYmVFW2baxLZ5J7Dis3U57W5QlDfPcgjDXMocbe4oMWzn2VQfnJz7HFFR3XMpyDnHpRVWMjyo9KI+9B6U5BjOa6zzxw+8DUgI3Cox1py9abAlHSgLzSL2qZB0A78UN2A2PDsIUbyK6W0G6Vc568VkaZH5cCjvit7TVPmpx7V5lWTcj18NG0EdJaoyRIwwOOlNkcO/yjGTyKt20RaNcHgiqjqRcEfwr3qZKy0OqG5MnzYUjDCrsEWSGHJPWq8Sqcc9ehrQteQowQR3rNnSkTC3AClg2SK1LNVe2CM+3LdM4qtIvCM3UDj3FaWm2QlnjL5+YZ5HX6URWoT0jqaGkRCO7kEP3thUerH2qwLckMJFCbeoJxn3q3abLVvN2kPHhwcY4qTVbizispZ7kEFz8iY5J+tdKirWOCpUd9EQSL5GmNISPK4Pl5xuq/o91p72s9xPNFYxryqNzk1xb6z5+2GRFdlyQ7cYFYmrXUk0qhm6DII96TqKCMJU3O6uJq2oSzXlztkbaznbzx9apxcfM3JPagx4Pv1+lIfv5PTNckpuT1OpWSSRMHxyin1xnpTt7MwG05alijO3cBnjNTxwkMpbO5h+lJO4mxu4javQdgelW40CwtJITvk+Vcf3asaZYNc3IUpIwAz8vOPars2nCTJcSwuOnGcD0xVeZDlrYx2jUMEEvTuV4qZbYF2KuDtGSAOtXJLCOFAwlV3PO7acUsGmyXYDq6hFzvxjI+lK4c+m5WtbeRLeUjG6XCqQcH3zVm1EsYR4sRK3ypxuDY71dl0q6O1rcfOeNqtjHuc0zde29kYiDHsPzBjnA9FxzzVp2Mufm2M4tLPcbpVJ+bB4xxTJ4y0zALhR0G3tVpXeBfNKsHyCARjmmPNxufl2HQt+tQp9zTm7GUyFnJPGzI56UQZZ0YrhRyfpVlmUkqRg8dccCmyBVVNh3Fhl+2AKNyuaxWkkcFnViATng9B6U8XMkVqm3DM5JPGadKrvtjC4DfMrY5x/hWZLI2WK/Nzjd2xT5rBz30NK3usbQY2JY8gHk1q/2kFIhjZlwcttIAzXN20cqJJcZwFFV5rhoowpAZ5PQVoqjgKSUmdDM+oXUyyM5dWbCnPT2rU+13FiqSTIzMvoOD9TXLafeTWpD73wp+71rRbxFdeSIn2EE8grzirjONtWRKL2R0sCm9iWWaPzCTnCDlf8AGr1tY/aXZSoSBO2OT9a5/RfEIMJMu2Jl/iTv9a0210S5tikayMw2zitYuLRzy509DVit4r0CGeBTHyA2Pu1Hf6TNYx/abKTzIF4YHqpqKeWeFnXhyw6A1Jaa/BDutrhygk456Z96t8vUlOX2SnJdpJDIlypOevqDWdNbhpGCZCEYyR1q7dxtBeg3WySGUZjkB4NRo6RhEUAqeu6s7a2Z20npeJhGN4GIcbWJ6g/lVq0jeOVWLKd3Y966O60v+0JAIyBvGMY79qwr21kspfKPDJ2PejlcXc6I1FVVluUL8FJGyhXNUmlAAx1rTvZnlgKHPPesMowJKr7YNZydjSnG61NizUoFZtoRulMZlNwyk4J4z7VTFxiL5FPHX60+0uxINsq5UcA1omiXFrUsLbFScEkd6aiETqQf3YPPtVuABVKLJktzk1Bd7RIGjOdo+YetU4pGXO27FyKzAdp4X+WkmnNuVMmTG3BrJnvZ02mBsA8YrVu8T6PFLt57jHSqjK+xjJOLTfUzb5pGYrGCY359aoR200ILEcela+maiIYhFJGHPqaztVvt9x8i7Rntxk0O29wd17pbitprRZDDe6XiYDeso3dO3SsfXpmFov77SpAXUEWqYfv7dKQzlzsx2JrMu7aVkd4IZGVPvFFyB9aGZtW3M24UPITgflRTDHv+Z92T6GigyseRGn+lMNPrsR54dOtPAwcikXJ+91FOAoAXJ9asQAl1FVwBkZq3ZYM61EmNK51Onjci57Cuh0pN75GOKw7KPKgdRjmun0wbU3beledL4j2aatFGuJfLiAI5qJSWLDpnnmmCTewHUYqeJMNzSepvDcdbhxIMg4Fadoq5I6EVCYV2KwbJNaCqodSgGMDoKza1OuJe8kyIhCMcnaT6V0unJHcXVoiBt0SkuVHWsOwLjCEEhugB5rrNFsfsqpJLGxlKnBxzu9K1gu5zYiSirXKOqN5920EDbVICDd6d657XpYv7dtdPEji2iGS55w349q6+9trfTdGkub4uLhn+VfTNcbJZRSQzXTEuxGBnknntRK8XY5OZNGY4G2aFW4Zzlx3/APrVXKbJMoA2R19KuhfLkIjUsp4ww5FSfZGEgR4yrdh3rGTuNNLYypUJJYZx3zWrpeiJNGkl5MtvubCBhnI7mrg0csuZWKKBkLjv70sVpMExKxMuNxGcbRThHW7InO60ZqLpdkiqZ7j5fuqsYznFPOk+ayMrqBgYBboPU1YkVYobUbJAuCS23vj9avWd5G1hCFXzFZ9oZl5/4CfStfdOa8jCit44JSCWKHlmRs4FSwxQxTnyPOkJ5O4ZIq+5t7t3jjikLLyzDC8dxVe3tsTEwEyoeq9GA9cd6wlpqti0+j3JJrFpLBpY32qeVXcRk/j3plnDGkD+fFMj7cNIgwPxIq3I26NYRIJInHJIwc+maW1hUvsLFoiuCm7bk+hpppvQlt21GNb2xYGKedjIm7ax+YAHtiqNzbyNeq/2jynGMoVK59smuiisyN0UZETAbRkE4+npWbPGY5miLCTAGZN3c/XmrknYmMlfUz7q5nMxQzK6YAZSB+WTWdcQMACYoSOu0EVsS7I1YELIDyzFRmqM9xEilhFGNo9Mk/rWOnU1iYYh8+bLKEC/M20f0qC7jWWSTDMMdcgdK2VjxCI8lGkGXOcD6Vm3sYjtljKrLuOQ205ye2aNEap3M15Cok2EGRlxhSQFX0FUoLS6edQFZozycY/Wp1jlEiRCNo9xypKHc3tmprjdbQyujyo542FskH3qotNik30Kl7c/vWV5XaCPhcdCR7VThkaaZWkACjgAr0FQSs29Y1JH94Ajg1dMnlW6eWFkdzj5gSRSbuxpMszSQDfuXAHOfU1Q3o82CW2txwM1Bc3i7zFHswDg+59amWVIocg4YfMxoUrsd2iW4njjKpGdvGPxp9peSplgxOPWslyZnLMTg4JIPIFXIWXyyQ2MccU23e6YKR0Vn4hurdAH2tG2CQepIp0k32+UsvLE9O1cvPIVA+bJPb0pbS4e3ywdt7HIAq41L6MOW2sTq0W8WAW88m2GJt8JJzz6VfS8ku2HnYWQjouMVUiuodR05AzbJQQxPc+tWGs/Lj+1whnhI+8a2CM7aPQ7W0KQaYGuMliuVZTyDWLqKi+z5rIHUfK3r7ZqHQrksfs87mRHGAewPpUU6bJTGf4eTitm7odGPLJvqV2tttunI4OGz1rEvYmSTeCDHnjFdHbI5064MxYkH5GA61hxRmd2iBAYjjPSsZx0O6j18ilGpP3R8x9elQyL5L5QYJHOKtzRyQSeW6lG9T3ojYHfvwcLxmpUTSWjHW93EyBZzyvemyqUYshDI3OazskqxIwpPWpFkKjZzg9s1Sk2tTJ07O5Ir7MKw4zXR6VLFc2UkGecdG7Vy0hRWBXOD+NaFvdm32uoBwcH3q4SszGtDmWhJdWU1u+5E4DetY+rsWmUvy/SuwtVfVYZJ1HCfe5rA8R/ZiI/KwJFODVzS3MIyd7Pcx7aCR7a4n8wIqMsaLjJd26L7U7WdPNvFcfZr2V3t5VS5TBRQ5HBBB5x0qxoMlyjzGN7ZLcOhZ7hdyrJn5SB/eqG/F2NOmjeSF0S7YTsg+dpMnDN7HnFTHUVRWZzbOqHDDJops8Z8w9TRVGJ5CacpLfWm0qda7DziYfN0NOAHNMGQeB9akRcUnoABcA5q5p4xcrxVYAn0q7pcZe6XJyOorOWzLitTrtLGWGccjjNdDAGSIYI561gWf3owRiuggRiCeMDvmvPbuz2oqyLFtzk9cVpwqrFSM4PUVnW67n2g4Xrn1rQtxg4FL4UbU4lpAu7GDtBrXt1Xy8jACHA96o2kY+YN0YY/GrzxCJ41Y89eD1peZ1Lsb+jSSJcRBQoXOc4/rXoMd/JcafLPEitJF98MQefUV5/psojVfl3Z5OG5A9K663uTFE8aYEN0mwem6umnsedioXd7GJ4gjnvrhYpHBQneSp4Ge1ZF5arAU3cKDwFNbNrM9vDe2twgE0UmSR3GKq6vEktvDIi7GYAtJ+PSsZNfE9znu78r2MbVzDNcRvbjAXgnPBNac8H2hbcOgS4AGQe1UzLEIQmzYsZ3A9Sxq3bvIqGXoWOG/8A11yuqubUbg7I1FtoUXczhiQQ2R1NZUt4kWoOwKhnXacD7pFSXkrx2+6MnOePU57VlwWM010puI2RGy3AJzzTlVctIomFNJc0maBuWTSTLJIJOWKZHPp+VR6LKqWStcDBVjtBzhR9K15dISaxzbgAI4yoAyB74qC5sbyO2WNYDJaP8yyrGMhs8qT6U5KXNfyEpRs0T6atvHbmVTuJGGZhj6cVJpcavNhxuYDjB27TmibS1W5jjkkdMnBQ/LgY4z+NX9L00b2MioojJUKX+Zj2JpKErrTYzco2ZauY7S4Rv3LJNnBP3V+uKqz6XJF/qmDx/ewT83sQa2Vsi6XDOqoYlypcj5uO1URdnyjnI45IOMV0OP8AMjBNrYrLpl5JDLtkGGHzDf8AMwHFYWovdWbtHMm63OCyquG+ma6rTJTAzuxBBbO5ycY+nen3ZCOLeZI3/iII7ZzzRy3jdDUmpanEW8tuXISTygTkB0yQP61dks4ZSJGu4WjUZ242kntgVrapo1ncWsj229CpBUqOF56Y6/lWSuj3EOUuIpJMEhJFGcehPfFRKDX2TVTT62KTWzSB3ZQ4Qlmy+SB7D+lYslvPNM0VqszBWz8vyoOPfvW5d2txCvmv5cuTkmLsM/n+dB3QviKVRGVyBzt3H27Gs7W0aNFPqmcy1nqH2hWu1kSHOSM5OO1V9UiuGlMjReXAy/dZODXW3dxlFgkAMjsDuVhxj1qlqkRMsMFrcziAn5i/IHrxUPQuM76tHH29mwHmSrHhuF+UcLnnimNChklaSNCcfLjIwfauzntIcLHHLJMUOC2wDI74B/rWTe2ccTKd0sSAY+ZQ3Hrkdqh32NE09TlzpsU1wjSIEEY+YKNoAqjqPmWrDEYWMjJHtXaalYwQWAa2vBdM5XfGRjH0qrcxI6b2Cs5HdR0q2uVaivzbHDJiSVQGOwjLYOPwrTU+WuSeFGauNGqTEkorNjgR84qpd3TFfLMa7c8/LzihNWBqxA7APuUg8Z/GkjkKsDnk9cio2MciKMsGyWJH6VaFphFInzvOArCrSsS27l6OeKSRASVVehX1rpLPU3tY5YvNSRSR8p6CuR+zywOSEyyddtQrcujOxLHIIwe1bRqW0FJX6naW7s7k2r4XPz44/EVu6ZbtPIwZwCRgljz9a4rQtVjSfY2FjxyR9K149RksZVnVkMDMR+dbRl1Gr/Cdw72sOizxq2WTC8jqa4WVCW8wAcnBFdpcxwPoqOVCs7g4z1rjLoqJ2PQBuhHBFVUXU7MF1JriaSRFgu1AC87gOQKzRlJiqtlen1FaAKMp8zOOxHWqFxhX/dAkAdTWTep1WtoQSBVYqMlD2NQJHk717enNTsimQ/Njj86jWMxuQuVJ60yHotREH7rawwc9e9WpUSO26tmnbGdlbb90c5qO4mYxEEYyeKpR0OZyd9B1jez26yQQysiyDkCsS6jZZ2ErEkH1qx5xVwwJ3A4+lF8hYCTg5H60PVBZRfqT6epEDxS21xLAZUlDQLuZHXpx3BFSapkwXC2dnfKs8vnzSzREdM4UDsOabo91K9le2kN0LW7cqUZ22B1GcgHsavR3FxYWttBc6pG1z9pWQHz9wjjA+bc3ofSqjsc9Tc4W7MizEAHHsKKm1K4imv7iSDiFpGKD/ZycUVrdGB4xSgnNJRk5Aro6nnkyHOfWpV7fSoI+CTUikj2okNMnXkCtDSxi4UgdBxWchAx2rZ0gDcHP4VjN2RrTV5WOotUz5e7g8VtwRPGELvtRzzWHF9xSD9DWtbzNIqxt0HTNcD0PYirpGhwXCxMTj+KtOzBII+6Rxx1NZKrhgAMjrnNbVoM7TjH9DRe+50U1Y07aMbRuyO2DVu5iy0bMASeKgtH2ud3zL3zW9oiRXDta3JCxuMozdj9aaSehpz8nvMl0uwlnTMQJcYyg7D1rdWaVbFrS9iKCM5jkHG70zVeD/iXzyRyF4pkP3o+j1Nfxy3dqilhv5Pse9bJWRyzfO9diTQ7SO8FxDJIxeRt2M+3rWT4mQ2sqW6hkKnPrmtPSp4BbqHk8m5hYHcTjg1c8R20bW0TyN5jg7tw71hUh7ujOSfu1ddjk7Wye6dFGcucJnnnt+NdXb6N9kjjTVgYi4yQOT/8Arpum2ET2Vm9mf9IGWk7MCOlbcUM87IZG8wpgk5zXKqPJ01MqtVy2Yl7p9isBa2hBWJQQWGMCufu9atYkEUkTmMKWJjbDeucGuvu4wkDAuzSMhLjrkegry7xjPaWNhFd3Jd5bP5mjVsFlbIK+/atZScXZIilFSWpv6ZfwO8oRisDICpweM9s11Ok2ymGSEMZIFOVYdyRXgPhfxNqOuauL2CIRWtjtH2VHIDr/ALR7mvVLTxQZtMZEsLq2lKbhF2OD938fWtIvXUKlJu3KdDfRRyn95KquDtJyASR23GoJJJLGN5sLPJHlsHj6c1zU+h3Ov6gRq0r/AGQRboLfcf3ZJBySO46Vp2tjM8hh82SSCI42semP51E521ihqmrau9jPv/GGs6lbXts2nx2zqm0Nuzjjnj1rV0HTvtdg9z5zqghRQOuePSrf2BLi2uJXjjyO/cHFP0aCR7SSGN/JeKPMbY6gdsdKVNNyvIqcoqPuqwumTzeXhYGVl+U/LuLfX6U42Nw1vLPI3myuSWcjjk9K6DSbfZayRXEnmvP8zb+gz1A9qyrqE6dDPBbsSYwCkZPBHt6V0WdjmTTdkZlvC0FuEkIhvARvAJIHoRUrpMVLIwY4yQvfHrVfxTrVu2lxq2ZbmfarKg5XIHNZVxcarZSqsdwIkO1gxAY8dF+nrWbb6Gsablq+pYvPNaIzHaNoAK7OcHv74qtMLbyvnRAWGcoQcevHY+1cd4ng1FIXKXEpknyS+44BJ/lW/wCC9Yi1K0dL2OODUIAFkYD5Zh03Adj7Vn7Xn91o1lQcFdO5X1MBSsUMgaMlXYjpj19jUXnhnVQ2zHQhf5Vv2VvaXV6YbvcY13EyN29AQO1eYeK59RhvJHgu5YLXzf8AVKcbVz2rGSvszWnBt2PQbOINlmlkXzDySMZ/+tVSKCWedw0fmxKPl45A7Vy2g+JtRhu2a5DXdv5RWOKV9rqx6HcB09qqRazr1n57S3MnnSKZBuUDmrUL6thySR3k0ds8bCe3zjn92MEH8azLi0uJo0kilXAB/hGMVkeEfGmqzeJ7bSvE7JdQXs4iVwApi3dB9OnWu/1vSW0ueRfKl3bgqAIMNk8HPTHvWnLdXMXeDszjdV0OW6tIZbYGSWLKkIQWx+PJ9qwZrCIvFHcRTQyL/rVf73sRXq1zYxQ2odoxJJw3mxHG0+4rDfT4tX1JzLctb3SnHzjaOOo981fs+qEqjW55jc2cSak8IOEX+FV3HFXo9NfKyRRuI+m5h0rqNd8M3mn6lK9t5bKw2sEOdx9vwotLOS4ssLHmTkMMY2nP8IrPllezNPaK10cm9tIEwNwPOSeM/Woo7QmKZmxkdhwSK3Ht5im6aM7N20ydifSnXFo0UQKEMpGPl61HPZ2Zdk1ocY0clvJ+7YAdx3Irf03UIZtPMBCmTuCM4FSS2m8BgufcfyrHvbdrWdbkNgAjOOPrWtOpYOW56Lp+pvdaXbWpiX5M7XH8VUZl8wMzRj5eSe9Yvhy/K3aW+0tDJkp833TW5OAIpYwQzZABFdHNc6qHu7GfbB5Hf5SSoPHpULj95hRtye9aU9l5VjDciVSz/KUzyaoHgkEbhnGPSoejOy6k20VtpJkPyg1JEFlhVZOJF/j9aQ/ecY56DApXBVN6gcfKapOzM5q4puGiBRwDu6EVRdmGQBuHv2rR8gSLHKRkDrWfcKV3yE5BPatFqc/UgvAgiG1CCOtQGQvAAG+72qWQmcA/xD9aoBXVpFC4PvUNW2HZWNPSWhgs7y6e2jupEkjUrINwRDnLY/TNN8YF20y/jW0ggSC7RVdI9vmoQSMH1HXiqGmLbrZXlzetcOqlYjDA+0sGzy3+zxVTW9Qtbmzjgg+3gxkbBPPvRR3AFNO5zyWpiRNIFOM4z60U6NnC4Uj8aKrUyPLKKO5BFFdx5Y4H0qVTke9QIQBzUgJHTvQwJlbGM/ere0gAxKT1rnx6nrXSaIA0Ix64Nc9XRHRRSckdFEmLYFeMHmr1idvzD2wKrqQtoo6Gr9rEFiGGyx44HSuBs9mG2pdt2HmqcYPety0+YbeB3rEhAEuBuzjnNa1juZspyTjmmtjaJswOT8hUkAdq04YfNgbaTxyPU1lWpWKQM5JxwQDWrBtjCnhg3Qr2oiaM29J1CKNEgv1LxqOWYZwPetOzQx3O+wlimjOcKHHK/SsGAu8mW8sgDndVo6Td7fNVACvPyHn2xWykzGVOLvra/wBxcKWdxNNHeRttJwGX7y+2KimkmjLWgTNtHgRy5yzD0Iqs/wBrQ75ywKnvwTVmS5glm2+Y6RyLtz6HHY1lOS6mFWm/UTStQDq/2dXRdxVpTxj2rqPD1/CY5YC5Y56DkMPT61wVv9stPtcUm8AYIkx1AogM9hraTo4VZk34LdTWbvFnLOmmmerMjFkDDKKMDBwQK8t8ZC2vbh9PbJneQlSemB1Oa3J/FGpxMjxQrNEwBPHKmuV1rbDfW+qX6kbNwJTPAYc8e9KUV0M6UWtyn4W0qDT7ue0tIhG6gv56kENk8qR7V3Xg/TStncNcOxKT7VVmJJBrF+EkVhNp01yy+ZIZWOZTnCn0rqfK/sy8NzGQYmk789uoFa07Cqyb0W5qWUYWRUz5ZLYPPK/49Ku21okd087EIpBONvB+tV7iJJGE6JId5yFIyc8flWtDEyqsLYKkd/Q8UKNtGc8pdUULqyjLSYUqZsZAGR+VVGU288ZRvLU/IePb/wDVWpekhNrZEqYVWTPSoNViK2KkffVx0P3RS5dbroCl0ZUW+iTyVkYqd+3cT3OAePSqHjB824a0mLrFtZj3UA9/wzxSyQvqMqmJtiINrDGHyD61z+uCWzSUWTzLFIMSxnB3N0GDTnNpbG1KmnJdzX8201O+VmZY4I/lV8kfMMce1aGr2zS2xabyXRQXDE4I+lYSx2x8K+VcDZK+5iyHB3r2b9Kd4fma90s2975kkGfkkkyeP7pPtVRaa1NJU/tJ7GJrm6XEWN6yDAT19gaj0vTXgbM8BieJeSfTHY/lV+8Tz9XiniTzBE4VBnqAeuK6qS28+YRMioGwzMo4+n4VCpq7Zc6nLFLuc+8K/ZpZFhdpFjyFU8uoPAP40mq6BaDTTKsfzSr83mAHYTzx+Nask2YbqKBs8+WgOBhR1NaNxA66c8Uh/wCWeQw5VTV8iszJzkmeZeH/AAslxfxTTTbYImDeWF6j1z9at+KdJtb7UfL2SNFgFxHwfWtQXFzZII49mWGV54Y9gDRBA9mZrq6lMk0gBLAcJjsvqahpJGrlJvmbOC8R+DrieEOYRbqvzLMW3NntXfaB46ivtEbTfEkltBPbQrtuZHCpNj09DgVV12SW7tIltC21gC+7IP8A+uvI/H8BS+FojNJFIF3tjjJ7CuVt83KtjVQVSNpbo9cuLi3ur+3Nm0oCrxtcneMdR69afCZ1gMUoLoc+XIeGjbJ4+uK5z4QzzXNhb+YBIbadoCW5ITHH5V6hc6QkxLRMpIcbsj1PX86cVNXa6HPUlGDSZhLDdsIgoYxOcbgckHvnHSori2ltxKdu8swAdSC0Z/rXb6ZCUs/Ikh43bQzdD6VnSaaHuZbVpUjYc7gv5e2K60rLU5udXsjhpbRjcqGiURhxhJOFLf1zVLVLGS11B/KXdbNzhRwuf4RXoF5bCGJIr2FfO27mk2jcy9qxNUhRyI4X2RuQJFUcoM/eH51MqSZSq9jh7i2PzMgYgdR6H0rJ1CLcXR19huHU12OoaVc2waYxtJb44kz976gVzl8ZJA2CoVmz8vT2xWUqbitTenUuzm7EfYLrerkEHjArtIT5GkQpcxgSykspXg4rl72FTGxwdw4yDwOa17CSS8gj5dkUYyeQK0hI76auix5rx4LIGhzjLDIFQ4BugcDaX6kdq2dKkSFzDOEe3cgMp7e9dlFomki3aFrcL5n3XU9Ce9aqHPrcVTFKk7NHmMh2PNt5A6GoV2sVKcbuDn1rU1mzGnalNBIVbYMcHrWbIoHGAMcn2qdjdNSXMh9m3kzSHaJFA5X1NVrsjyym0q5G5QatbJPJjO3bvbOfUVUuJQZ3JHyg46VqnoYvVlTyyttGFJEmajKANIHbORUtx0B3dDyKrqxeKYk9OlPoQ2yTw8l0trftZmCK63LiSUqMpzlRn8DUfiOPUm07N9LbtDvGBGYyd3b7vOKkNzpXlKJNOuN2OT545/SszV5LEWhNjZzwylhl3l3Db3GMUJGM3dnNM5ViMUVG8h3ckD60VdjG55seCRnPNJSuMOaSupHnAgHNPAOaavHWnAkZx3oiA7knI4rpPDxIjHPc1za10vhlQYnz1yawrbG+H+NHUpt2qXyQewrZ0+IbQRzx37VjW6Aqp5xXQaevCYHGK8/qe2loWDG24MASQOfertiwO0AAYFIFO3HBPc1JbfI/zAj2qkrM2j5mhbgcHHetGyfaxCNjPBBGaz8FVA79eKt2SkFmPUng0tUzoSUkbEsxkdVjVRtHPy9ferkTzxyhYZGyOjZ4FRWM6C0MO1WnDg7h2ragto4LgSzwtKF+ZYwOG9jWyV9mc8pqKtYpyX5nZftsqs3QELjH1qusSSRSkxhlztUrxzVW7lM88k5URKzZ2gcD2pI5WjJ2D3yOorOUnsy3TtHQuSMboW0TTxpLGdoDfdkHpntS6rpUghjh2lHBGG/+vVeeMS2K5AMivnH41YttUe5dbC7cwOrfLIhBJB6DBqN9Dz6lLld0bGmQpPCiwruZR85ByAOhqG802G4juLedFKcrj29RVeDT9R028AVw0Y5JH8Q+lazCCFHlMhV1G5kJ5FUtdGcjTUro4bwFY3Gj3onl3i2cmFu2BnAP1r1C/wBPilsoZEXfNDlhkcNj1rBnuraSKAKinzJMoHGM/WuosmzC0DEqw+XA71SikRVk5O4thPHJFAGwqHByCcZq3NcofLbO7a3XHT8axtzLAzICASVwoxjPUj/CtbSZFbS3WfEhAy5A/wA81o02YOKTuWysbWkmSru3THaub1GSZ/Is1eMBZGaQuDwAMgD1Oa21HlRMI2LR/dB7qTyKw4Ea+aOGNv3om85yx54OAAfSp12HBK93sO0y5+VyQdq8s46kmsLWZkdjKWVWT5lA7seAD7d66q1s4bVb1TIjM7b09s+n41yGoaeZdbgjO8Ak5x3GOlZVE1ZHVh3H2jZFaxuvhf8AetgSSkZbnNa2labLNo0saysszsMDOABUWuD7PZWqcqoIHlj1+n0q3pWp+VeLZgKMjIYt3PO01pBcvyNJuThzRM2dzp0iJFtMo+8Tzj/69XZNcE9uGbhyCG2dvYehrKuJGub6XY3MjHrzge9VtS2x+UkCbV25xxlm7mlzWTZXs4ytfc1rjTY0tJ57SQtHcAAsW5A6nA96S+1m5EEduYxGkERZ3U/kKZb6gsUELugeOHarKOAT2FUpR/xMplZBOryY29MDrjFNvTQlQ195XNK5sZ76202a0TzWaBTtB46ZJrB+18Rwz5J35CgfMfYe2a7JL6PTPDzQRgDCttPfJ7D0FcRpdrJ9tjuHQ7oZBvJzjBPHFRLV6E0fei+bpsaOmQskFzdXZjVZZDsRTnaAMVwWvWySWMz3W+Mx/OMKM5z2HrXoesahayO0cTbAmQwRua4eZbm8vRbpOrKXM/zHOB6Z9amVNJmtJNptmR8NNdj0DxBEl9AxsbrkyAch/wCEt7V7y1wbjQpbhWijltX52nJdQe9eM+IbWOWWOK0iXaoG75QAO/Wu28Mzx6lp9tcW8sMl6qmGVFOSBnA3e+BUtuDtuRWpqa5z0G2u4L6wjkiuTHNFhmXHC4749Kp6iLuPT5pXljlKMJUcL931B56EVW0We3t+btoAUBgZsjKsPU56e1YHjn4haHpEE+m6RN/aOoPGRstzmKPtl27fQV1XTjdnB7NqVolzUdciuUllViWJA9yBVWC0uLqLzSVCsAjFu5P+RXNeG9d0m4i8uK4E90YlYwOuHR+hX+taOoapdXF5ZJYJsuuMRR/ckxwSw7Zrn+LVs6HT5dIotRWswWSHBMScKSCwP1HSqNxZnULfyI7e3hnilJLr0ZcY5rnPG8Hii0gT7LqU1qkjYkVPTsMelZ8PjW9QQx6hZRABvn8of60Y9frVt8qtIuGHlNc0Sa+tzYSyJMrD5sIdv3jn+VTq8kDC3j+RQvzgHGc1YfXZNYsLVXspUEeTvLZ8zngUXytHKxBRmKAErzz3z9KlpJ6bHbhqbjpIhMYbaXyAWx+Fa2oa9cytGIF8tIOcjnJxwDVFjJHEwgUOpXaq4yc1TDthlUn73zD1NCbS0OjlVR3fQbezPIF83mZmLO/U1AFHlsxG5jkHNWGG22Z5PmUnt1FQTFfKRdpBzljntVXKVrWROjYtyJtwjThXA6VnzxkRE4yGbAq89xC8a25BCAZZj3NU2czykM6iNOFxWt0YtNPYz7obJsOpyB2qlJMEtHVSFOc1YnklMpB5LHAqre2xWJdxAYjvQQ13LjwaYyo7X9yWxji1z/WszU1sltz9mubqR8gYktyi49d2evtWroWoPaaRfG1ZFuo3R2yRuMQ+8Bml8Xz3LaXdfa5Q1ublXsyGHzoQcjA9PetYHJN2ZwFyoEzc0VHNKvmHnNFS07mXMjz6Y/vG54plS3AAmbBBHSoRXXE4WrCg4NPphpV700Id0HFdH4az5bE9dxrmz0rpfCw3RnuQTWWI+E3w38RHZwbAIwCQD7Vu23yhAp5Arnoy26PGTg4xW5CcwKAMSHsa8692e4tjXgZT9707VMnLYGD7ms6BxuA3dO1acDQ+U+7cX42gDAFWaQWty1E443NVqEBl6nHQ1Ujj3IrLyM4J71ciPfgg9iOlS1qdKsXrOOPeSxOB6da6HMMEEILSlym/aX4FYMJlhZGZkXOOMf0rcQpdCFJXEZI2+aw4A9xVxskZ1Um02VHZFJZOYmOBvGRUEi4VmGCT6VdntJFtQYlMsKgklRkZ9fpVZkJhZiPmUDco/nU1Bxaew6yIIljwWyBgg4xULi3llLurEqcqV+8D3q5oSSS3z+Vj7hxn1q9d29lYzLLON8pJPHY0orS5zVZJTcWcxrUF21usdvqsyeY+d7MflPpUaxXVzeQBbmWedv3fmk8kdwa09WaTUwxgiBZOPb0qr4ZVrVri0uXiRlOVxyAO/NUlqYOPLG50dpp1va6haxbt5imU/OeSceldbDg6jNmRCzsPlzyB2xXI2MQtrmB2uy480OASOD7Vva5K0M8F9DBudQxkK/LgDufatUro4KicpJXNIW+fOdpGQFzs28ZOfSrkMC2tjIMnK4wP7xJrkoNRnvWiuI2LBSzMiA4//XXTwavbXsjwFthVVcqBwM9B9aSdzOdOSKeru9vLjEuGiBODj8a5O+vXjkMllO4mDfMFPIP9a2dd1W5aW/SGOPBbaQzZIxxx/OufezP2llizvQiSUNnnIxx9Kxqt30OmjDlV5HW6HAb23gvTmO92eWcjg+ufWpdWsFN3biSNlKurrIfut7VNpCxCAW5nET7QAM9R7GrYEBMcf2ky7Vw2V/lWqhdHNzWlzHPeIbcGTzUw23LIQePx9aZDoMa6TLf3JknnZS+5W2Kvpx1JrSl06O6gkeZ5Iot42Kv/AC07kAelRXc26EpExLlgpUD5VXPP/wCqrsbe1dlGLOdjtmitzcNlTuXC+o9/xqg0kk0vlRjJ64I5z3x6V0F5d2Z06b7Qw84EqAvVRjrj61y1jKUguZ3DKWG1CB6c/rWE1ZpI7KV5JyfQnuZlf7PExQiFgWK9c5zzjrxWhBLFd3V3ehWSNZMx7m5JI9KxlhC2AnZQshO456kHofpW34QtX1KN4okACnJZmxn06+1RG8pcqHXSjByXQuF0M8ZfBAOFU8jNaIUR30k8Z+QooZMcBu+KpaoIbG12PGTMHOWz0HoPWo9QuZFvvsqg7liDy7Vzyeg+tafDo9zjjF1FdE2qQWl/CCYY1kUYBVQP8muI0aB457y+vZUknUtCEA+Y++BXd6SsdwrsrN5nKx4PBYdTWNqCCz1REuflE24mRf6e+aiz3ZrTk4twOc1AeXZSKSJImXe7E4J9c+laeoSrHoK3miRQweZa5R44xkr3Dep961Ire01GCf7SkcojbaoCZLkDrVG6u5rXQk0wRKSVIckAbB7Grikm7hrKyjumeX2nhvVdWAuY3mgtN+Wld+WJ4zXUxaJFommCGaLzgoLh4wP3hPYetbWkKYbVFYuyzLiMEhRycce+a0LyOG2jEWxw8WUMTc5P94ZqVTja5pK/Noc7cacttotpd2UJ+27sz2yoB5Y9d3UmszS7XVRrEGo6letB5edkcLY47A12ekxsWmEmyWRiD5iHcq+3pU2ppD5EMG9FjVsOhXBP0q+RPVDtaXK1cp+Ibi6u7XbPO8ibQV4wyjvk96xDpKrbiX7NHKEz8wfPHY4rqJGtPs5iMIDqANznOD6VmxLbxZZHyIySTkL1OPxxRN3dwp+4tEV7VbiOw8t0VC53IqjBI+lMuLeK3jDOknnNwkOMYPqaln1CaRFj3/MflLEc+2KJGukdLlvmb7qgjOCB3qdzVKS1fUdp8rW7I8xjkDDgE/MPYetZl5ua9zEPmc/cA4U1fg8uaZpiDkJlVA2r7sKoCSHCKkki4clmI5b3ok+hcN2+pDOkccYVSwZD84IxzUcTJIJmmDMWUYIHT60XshmvJWd+M8Y70REhhEW2qR8xpLctqyGyR/ZLSNnVSznO3tis29kj8shQAWOcL2rSu52uAVCjbH0B7+9YU+yaUlQVJrS66GdmtZFaWMllIJ55GKp3ZlfapDbuOT6VeXa4LkgBBx3qhLORcktyp6Y6URTbMpyuakdrEuk3cyW/2m5QqoUZPlg9XwOuMVk6nEsnho3M1r5E0MyxxykEecDktkHrjjkVo2zwx3Es8LaqF4Eb2ygsOOQ349Ky/E04u7bdt1qWZTybpPkC9+g4rohscU2cLdzhZsAqOKKydTlzeN0OPSitFBnI5u5kzkea23gVCKnuhtuHBqAVpHYzluKaVcZ6UlC9TVCH10XhaTDMo9a5yug8IruuXwOe1Y4j4Lm2G/iI7iFf9X/tHr71uxKSFL8npxWKFO1BnpjitmxyYRnpXnR3PfexaCAYIADYzmp4nJ5Zcn0pyAbDnkg5ANP2sWA4+tVJ9Ea00W7eUgYHAPWta3wNvy7sEdPSseIEqQQeOAa07TIdS+dnQ7e5pK5pI0iRuMjsW6ZA9atQeY4MvO0NtyB0qoC8kcSKd24EbfxrdectaRRrnylVQxxjGDyfc1otWyHJpIia9axWJbdi3HzZHB5quZlknaaJPJB+8g5X3/CrF15Vze7EyYwgIUnDH3NVbiJY2wCxUDHA6iiSYRUe2pJa+Za3KTRL/FuIHT3qW+nWaeQq+4Nyp44FQwyKIpIvNPJyGA6+1RR/KWCfvST/AAjkCs+gSinK7I0VoXZScI4wSM5X3FZkwjiu5isxeJPlL425961ofNhlQzRsIzn2De1Q3Nul3e+TLGgZV3dOR+XWmttDNpLfYihkC6fcPJIpZZRsbJyTXfea02mrBuR2lUMGXkMPQ1y6aTbTpbRRyCO2C+ZLJnlz7D1rWhv4YZWlVjDbwJ8p25PTgVaujzqqjO3LuQpdf2bNJA/mQbDuA6ZJ6iptJVHEibPs0dyoO93yWbORg/0rndTuv7SvEl2vHBt+8wxux3q3eXBjGmwDbhSHIbkKR04+lZe0ab7I1dHRd2bsptH1Z7O+RPs8pwsw6q+OBmoZIJJtUDCTdGTiNG4IAxWaGa512TzJAgDeYB1XPH86t29rcz3h/eKzIS4JxnYSfyNO97mcocq36GzFKsVwg2LIFzhm52jvxU1qk7XTrHEpSLc2Ogb0zSWlmJVVkcIQuWJOAM+9WMZTlskjPrtPr71pGPc5OZbIL0GGOKZpGGxDheDt57Vl6ZtmaXd5mAhJKtjBPGa0L2HyneCRl2SEHJOcd/8AIqO3hWGNFgO1GO5ywwevAJ9farbe5V7RMDxBaQsD5SNtICgHnB9c+9ZUNswvra3hyG5yHPy8g8V1r28lyropJQEgADqfXNQS6P5JjZ43YsAxY9x61g6fNqjqpV+VWkcjexzhEjVWfyxswB93npXZeCYoIMwvHIJJBkv/AA4HYj+tQfYz56NtAiEnzgdx61fVBBcyMj7cnC444HSlGLjLnQV6yqU+Qo38P2nUnDSEIJG5ByPfHvTxp7319cTFnYjjcrbWbHQ8fhV2IyRTvsB3fOoBGSCe9Qwlg6SKMu3Awf8APeqe92YxnZWXYie7gsru+UbokskEanvIx7cdDms6GVSElu2VtSyflI+6DyB9avXQtf7NCwSJ5yznex6h8dPc4rMlu7WyuvMuBtudoby1B+b0ye1OTNowv0ZNNYSXZllTESQ5Z3Hy4bGAF9ax9SWS9ubeE7HSMYl2AkHAHJ9RXQ2epXKRXJhaEQ3C4aGQfIpI5IPUVi316SWS3kDyYwWC8KPr3olZLQ0pKTltsZl5dRh44FL/ACHDGP5RgelRyBrLfLcB5pJMBQx4QHsas2lvPIyNbRszb8nEfGfUE1ZutOkneV23T4cfLHjPPv61Nm1dHW+WOhXs4xa2f2m1D4YElMHap7E+1Z6QySMwudyq3OcEAGu1tLCa1s0RWdY92TDIATn39qxridHzLqAKyt821FHAHtVODsrmUK2rsr/mYbEtEscSl2Poe4q/PBHFdeXLGBbEB9v3ecYOPxqe0jieWe8iWQxoVk8pepAPWppp4dYuwLpTbrCn+s7EZzzU26BKWui0KiQqzxGAK0QON7qRjsc1ZmWRrcQDH2XJd5s4A96u6fEbrzpSEjsPmVAxHzcdc1kanM88yRW8x8pBjYDxgdeK0tZGSfNK3Yr3mWjiNq8f2dBtGG61kSxtvbYp45wB3rV1C3jHFnIWXHK4wBVFXSCTk/MoJIXmokrs6abstCpIjFtjAKWPHrVm9097WJd0g3suSp64qsHMshKsNxOc/wCFMu7lppvMlz52MZPpU2VmypKVytJIxJGQVxgHtVRAm5hwODz/AIVJcLlSqNjPPHQVG8a/cU/cGCe1VBdxTSK1zGyWoZR9/nFUoItkEmclx19BV5ySkrF9sUY2gnoazEDPMWXdtccgcCt0rM4KsjR0q4lSwvrezu1tbyUqULSbAyjOQD0B6VFNe39pa21tdazEbtrpZBm4DLHCB8+89MEdBUNovlabfXaWqXNzCyqqyJvEanOXK9+mK5rxfKLjwlNeXNrDBOlwkcckcXlCYEHcu3occHPvWtmzinI4HXJoZtZvpLQbbZpnMQA/hycUVnhuvPfvRW6TS3OQmveLlxUAqa/P+ksfeoaI7AwpV5JpuRkCngYqgF74710Xg0MbokcZrnfyzXQ+EG/0ph37VjiPgN8N/EXqd2oK4PUd61LBykePXsap26I8QZjjirNsh+8p57g15que6a8ZLR5+UdqmAY9xgdxWfF5ikZGKvIzI33e4+lPdm0NCeJzv4POO9alm4DbOTwDn0qgIgSGAK5Gfxq3+6KorKN47+o9a0Rd7m/FHJBdj5l8zIeN8cN7U92mlkABOWbJHbnk1Dp0oSaHzmI52ndzgY9KnZCZxsG2JJOm3qDTts0Zpu+ppWk1vDGwZmaZ1Lu7Dt/dFZk07SD94B/wGkvLkSxqIwFjiPTHPXufWp5LZJoIpotpdgdyH2onK+iHFKLvLdlTCupKnBJ9KjNyUmRLd2RycMwPU1csQIrq1fahLPtx1OPXHpVTUofsl46Lt80MSccjPWsXFpXNr3lyMebi4My/aZnlxy8ZPAwaju5BcsJYWkR064OSEz2ptp5uyXPMPG7/a46Us0Rh8p44yqsM5JIxz6Cnd2IcUnaxqWCTmRLYOGRU3JJnClcfdP0qXWLSdLP7NCfmn5fJ6DsPxrItLhbXcJw6qSfun9cV1CXUYaBLaMNYrtAnc4Mj55znoD2q1qjgqwnCaaRlW9qUsVjMw3qdmSOPc/So3t57u5dnBEPEYA7L0BJroVe2RJRIQrs+4RBclf8RV8SQX7xQ2wxLIo80FTtYjoaXs09jD2097HNaVYtHcSiRWIaNo8nGPYHPWtHRvKtUlEpZHc4bBzn2rVnsmS5QXVpLNgFkiTrkDjH+NUbgRrK6xRyiU7QQfvFs8UezcQc3U0sWrMW8llEIslhIyylgQA3YVchsjJMHiOzbljuPysKZpoUJ50gEisCWjz0PqferrW0ckLXFk24AAiPPX6HtinyS3MNnYqXKg3MpIjVCuQgOSCPQntU8i4iiUDOBhio3Yb298GqeoJAlzFHezqkjc7F+dgPU+nrTIdatraVYdOV5UJCsxJJ6+vp9Kauty1Qc1zJGvb2RSRY2JiCr04zIfU1UvFksisk8iiI4B3clSf6VR1XUtUF4qosUaEBhkZJ9c+1WLhr1NtpLGksbKHV1Xg5GeR3GatO97C9hJWu1qUmguVuJJ7WeFolGXtvMBJX19ulSXOpW9z+9dnRlxId0RGT6D1qhpsEtzcRtJAyyR8oyRgrjuDRqAnt7uNbm4QswVhkEHB6VF9DodG7UWzSPiKyEhi2MLmVcbgD8uev41jS3eprbxQxyR4ILAg4ODwOPbk0LYfbpJJBI+BjKn1+tMl8PPGIZp2Ee0Z3eYfw5qG5MunSpQ0RJEn2DqVMgUBBjBweSfqaqtbiW6e8u4xk8Ii9eOlX/+Jbp0X2h7gyzEfIhyxbHYms3Ury41m8ItoiingKDxz796JWSSe5rTi5Pm6dyK9upL2NbXywqht2E+bA7DjqallS1t7OIbYXuVGBk5B9c+9SrGbO6MUaN5CALMxPPPGRSCCzHmmWMlox8hD4Bz0JFCXU106beRat9VMttNFMixKg3rsGTjGMVX1a2SGBJEuXSGZF2KVJB+uOlTbIbrTSytHBNER1OA4PtUU73VrOY1aO4lwU2oc5GODjtWid4q5iklL3dPIjsrmAxLaiRz5Ssvm567uh56iszU2CXq29sA0NuSST0Prj2ouIDEjFY50bADSngKfp6VUlhRW8uIb93Ckjg+p+lTKTasdEacb8yL8UkiWUqJJGiSrsHY5PPX6UyX7VBHDAGGcAOoGQSfWnaorXDwIjgiMquFGMHHU1K8nnSTzSoA0C7AVzgn0I9fehq7MWrWlYNVdG8nTYHG6OP5VX7oY9eaz7qSS0it23x/agNm0EFh7/SokdJb2JVbAYY6dD3GapPvS7xCody21QRnJo5m9UVGnbQsybEsTctMPObhY1OCzd8ioZLKWO2ElyVUdVUd/rUGoyrNqA2x4OAuM/xdyKhmZ2yztkRfL7k0XRooyVvMryMrXu6HcI16ZqK5O6Rm4IPQUs7xeYdqldxxt7D6VXkcthjjHXpzU20sXoRuxQKyEb+4qNnURNv4d2wMVKpDksThBwCRzUIAyZiRwu1Qe9bQijkrS6FS4uVQLE+fLPp3NU5blokkjHRjnpT0j86ZxM6gqdwH9Ko6gVUb1Jz2rSK6s4asn0Me91i5t7gS2k7wTL8u5GwawvEF3LrOh3l7f3c9zc2lxDDGWkyoVw2ePwFdNqPiuWKJ2+xaaAq4G60UmuG1jxLd6paSWksFlDA8iyn7PbiMllzjJH1NbRXVHBUdzEooorYyLF/j7Q3oSar1NenM7EetQ1Mdimh21R0FLSBhnrS1SEGfwFbnhKQJqGD/ABdKwjV7SJPLv4TnBzWdVXizWjLlkmeuWYBjxjHbNXLdwjMuBsJ71j2ExMSEnjA61oq+8BtxLeleZqe9FmocEsQOAcc1NEQ0bDGT6+lQ2T/KN4ADcEn0pV+SZgM7c+tUjZMvQE5wSSMdqsQljwG+Q9M+tVIm28ZIY/rVuOUmNRjCg8EDpScjSJoxyK5CsWBP3jnqa0Vd/MUkn92cgA8MorGtmBnBCnI5257fWt+1kgaKVnJETINq46N3zVQ1FNKO6ERUXBwfLny5OOnPb2qa2GyCeOZtk6glST0P096jkjjaWFAXEO3JLdR7e470ryySWUisP3yjyw3Tdk8kmqSZPNoXdLs5ZLcXG4K4UsrbsFFA61la1C8k4uYfMZCuWZiDn34rdv5ntNJgtIYgHusIo6kgDqKprFbDRzvkj2uPKxn5mkz1z6CiSuuUmFRqXP52MV3KWoVpG+YZGw8KeKcrSsxi3th12lScAEd6Syia5xbCQAGTKnA2nHWrF55f2pBDjaoGewzWfmdTavYtWNiZre5WUM8bQ8SEZORjAwOgp1hdLbed9qyImUZRufpinaZdOskkZm2QzrsY9x7U3T5ntLuNJQGt4m/1ciev/wBaqWyaMHFu6ZLbTC1t5dkLtcllwZGxsQjPTsTV6y1LU3uJIokAY/IWX+E9gD6VQtbV7u5iRlbyufvMAzDOSM1r4+2s1nAEjTcfmiTk7egY/wBapK5nUUY7r/gEUs19bQieW7BlztVZJSd3Y/KKhm1O7J8pI/nC5wpyrZ7YqeawRNRhtEDNcRLiV1O7YTUs8RtzJp9sAvAeSVuWUD0pNslRhorE0euXFkqJdxLuJB2rjP0A7UDV7vUObdjGUwxGzAHPbH9aa1rBYxyAMkrOVPm5yQMcjPrmtO3kgS3WGFUaSUFz2AJH3eP60uaTdmzOSp7qJS/seVriOTUpZWbncq/eA9M+laZFpYwwLBGiJnqD/T9aSWG+ghRbiFZFYMWKvvxxxn6VUWXy5XMhBYKCq44ycdfShJLXqTzOa3+4tw3S8uYYLgxnAMvLc5OPYVPF4hjaESXMIiBYr8h4I6jFUkX7ZARcSKpPyqIxjb3FZrpZtMpaXYmQpDZOMVbbjqhRoQk/eNabxHaJDL5al3H3AAO3Yk9uaisryLV5JcxKksEZbBUNkZ5x6Gq/lwFw+Iwm7DMcBCnpioLyODKSwIUVwTkPgAnsPUVN312LVKFrJWfclvdHzH51vcoqHAMe5eh9RWVqGm3s1/DazSFo1VQvzHaBVu8sI7aQhJ1bjnI7nqPc0nny28UUckgBJ3YI4C+/ue9TJJ7m0FJK61+Rnwx7EmikJkgTgJGPlAB6irIkhhMMdvN5Vqedq9VB4OT3NWbU3DCfBRYkOQ6j/Wj+6PQVHHYpuMhRlgljxu6kc56DvS5b7FSmm/eEZZLNgGhEyGPzEJJ49z61CZYP7JkgkMQmMm5RtGR6nP6U8+Wkbqs7eShIJJO9/oKqXEUMoBCjkhcKeAD296q3mKKT3K8pKKCrbm2h+nK+1SJDH52RP5UgP3vU+g9afKRGzLAzSNtBbeACcdgO1JIRJFGkgbIbt8pyR0/KktCnr8yO+uZ5WJcs9qDsjzwG/wAao+YYV3uCQvy9cc0pjYyrFOxjBBA77R1FRHbyxIUkYQA8A+v4VDlqXGMUkkPhdEluJJcpvXbtIzk9s1NLO9vFaQ+YirK4aQqOMev5VXtSZGdyS0cbYB6kk8ZNQJPCdSSZkZo0O3aeMgcCrWm5E4Ju3YmHlJrFw9v5ZjiZmUZ25X/PaqFvcKhnfbJuCEiRT909qtQTG0d0IjdZiwZ3GSqnqfapIovN09bWCUeW4Mr5HITsTVJdiZSUdzADfKp27tvUMO5pUQRzKlxubJ4RBktUl5H9lG2OQv6kdM9qdCzQSRznc7OvDnoBSS1NZyutCC5s5I5tgI2Z3cdRVDU8LMUjJERAJGKsXT3EztckhV3YDqaqvqktvalJVWQO2Rkcj6VWmxk+bchu5QhjtIyMFsk1FIozLISRFENq49aqPZyXEiPbyL8x7nlaNQaS1hMMjfKnUf3jVxu9zlqtIomYSz+YRgDj6/Wqd5KokOTw3QVFNJvj2BjmQ857Vk6tKsEDbn+6PvD1reCsjzqz6ieJdK01ba2nl10R205bay2bthh1U4PBHpXJalZaZb2u+x1j7ZNuA8r7M0fHc5J/StGfw14imTAs5fs8hEwXz02tkcNjdjOO9Z+paBqmm232i+tDFDuCbvMRuT0GASe1apWON6mXRRRViHzZEzAnNMHSnSf6xvTNNqY+Y5MAAegp5pqU6mmIACRnP4VZ05d17EM8hs1ABheamsCFvIif71KWzHG9z0jSrgCJVYF8DvWtaTgMcjlT+lYljETCjKeO9a9rhXI25SvLb3PegjfQJIgeN8NjpircStNEIzHlv4CKp2cYEW9BlelaELnYBggg9qF3NyA7o5CH4deMmrEUrGMgcoepq1M/2ggSEAAAZA5qqsJScxDnceCD396lrsbQl3JYGMcgyMHHX2rTiumWwEUnKZyD0Iqm1s4jRgvIJBHofrVpldVjidQEkX5Cexpq6NJNSsak0qukbyFvn2lvYr2H1FWkuhe3ITaShb7u4Yx2FYly7LFbBjtYZQgdsHtV3RWk81fK2jPV2/gx3rSMnexlKC5blvWdRW61eGSBh+5UqFPCLgYwPWs61C3GY5mYIr8Z7Z5/zimLGCW28KOpIznnvVm2bdLJGgUODuYk9h7Um7suEVGNkLaJCTII1EjBwUIyCPUgVduCZiEi8sRMcSH1xxnNQNHJHD5vyII28wPG33wT1HtV23jjuU3WZMmX3yQH72T3HqKLXQpS6sbawLLA7KBsTA2jkkdz9K2Lq32TRTttlDIxfC4BHQY/DvWZeTSWU+Y4jFImQrKvJ/2T7VXM11dxj7VcMI1yUHXOe30oclHRmbhKb5uhfji8y8W3s3ZWAy7uQQvrj3q018bC3NnCfKlf92RjJ9N571SuWt4Yre3sVEk+NrsfU96ptEzXUv2qfZKo5bk5x9KlytsWqalvsdDYMv2RoYJGWSYt5srEElhxuB/pUY2QxQLdL+8YkM+4Od2O3tmqcZtEtpUDAyBeSwI49at6RbRNHK2ImDfMCDjap749ata6GUoqLbYsZWPfFd7ZJUYEBedynqOKnjt52dDDFtDgqo34PPqRxQnkQy2yxIwikG193Y+v41PJfy4e3hVo44ySB8pYk9adu5Lcnt+JZgs5bW0lSQNLMWPyhyNhH8xTns5ggURCWVv+WgJUfXn8KpQqXnCbS6SAqPnJYfjWu6RxRMjA+WpHBYcHofxqkrmEuaLv1Iw8UE8ZkgnkVc8qcgHGOKpTi2DJvt5xydoY7cjjjArTwrHzGjSNhwHZSWI7n3p2pC5JRoVMuMNgxgbR65605RFGdpf8EzriwiuDBODHAjfNzwwPpipJooDbLG8o3R/dLr1z6c1YMe+WZ5p1j5xgZb5e5qCeyjikV4tkpyAj7uc+pz2+lK3Ww1K+jZSu9OaeJUtmgfdgM28gg/jVX7LaoUglZ5wjk4CkKG9z1xmtO8JuBlp41KHnZyVI9arahFbPK8lu7vKygrlsFz9PwqXHqjSEm7JlS5PmySNDcbiny4C4HHUKPSmXF8sv2VbPchjAByR75x9aWSWZUdQsZBG0njIyckfWnBABkkfaHxsVV27VI5OfXinvsa8tt0U7gW/kiQMyvuO2NT90DvUVrEZ7cmBTuQ8SEdPZffr1q9DbB1e9EQFuCVjeRgFYHqSD1qM6ggVzEzNGVVACpw2fQDoc0rW1Y+Z2tHUinjt7EK0RLvv+YtzuIHGPxqta2s0cU17c7cuMrG+VOfXd0x7U62LupnuRkq+2GLGMnuSfSrMQa/j2yFhGhD/Mcbz2PtwOlNLqEk0mmzLe3aaSSa5ljWBMDGducdlHeoAiG3lkeMl7k7YVH8IB6/j0zU0ymeWaWf5bYPgYYFmPoD601AzvHLAo2RtsBJxgk8AD9azauy15P/gFa/DWdlaxp5Z807mxzgjgg1Ttx8vmBU2pKCY2bGfQCrc0bEokwDAHYjBsEjvUFpDDJcvbw7G8xjHHI4+6fXPf0oavK401yu5emu1N3cTXiCO3wPLRUAAwM/rRdzbLpyQM3UQYoy4MY7L9KjggMMFssn7/AGktKFbJTb0H581QvFnuJpLh5CsjHJMhwfbBrVN22OZRjKVuhVuoixEVoo3MN+V6Z9Kr39y8sEUf3QGwwAx0pZL1kVGjPznhieScVBPavHYebHuEu/LccAH1qU+xvbltzCXjtIUhG0RxHL4GFHtWbNALkvOYz5UR+UHufWpr+9SGDyEIJPJcEdfes2e5kkAjUlEUDAH8RqtLmbukVCkwn84ZVc8IOM1Xv7mVJQXG8FTkN2q3ezyJPBHHGCIhlj15rK1F2JCscM53MtaRXQ4astTLmLupc8JXK+Ir1CPJjOcYy2ea39c1D7PpskOF/wBlq4CRjIxJ6mulI82rJbI6OHSNa1DQ7SF4YI7RGMlvLczLE+1hyFyc7D16day9V0W/0kRtfQlYpeElRw8bH0DAkZ9q1tRbR9fuVvZtWNhcNGiSQXEDSKpVQPkZe3GcVXvp9PsfD82mafdyXzTzpLJL5Rjii2ggBQeSxzyfSnsZGFRQOlFUIDncaKjZ89CfenA0AOpynJ+lNo/E0LQB+7LYyafCSs8bcYBzUIOOtLvGaTSsCdj03RnD26KxIBAxjmtsRMgVuwrlPDN15lpESMlQAMV2ts5uEViMDpxXmuOrTPbpT91MvW7MURVJCN1+tWImO0tu+YfrVaOEBjEpLOe2MVYgVlBMieqn8Km1tDoTvqSRuDuPOTx1qZWJkT/ZYYArPEoLkcj0FWhlDGxPXBUjvWd3c6YvQ1ZpGdplDY2tkL9afPL5xiUdUXbj+dZ905FyWXc2T+dTRPufc/BPT2ptlxitGTN/rFLHPPY5rUsZWgtLna6YlAVgTzz3xVGDY0NwhwZflK5Gec80spXfGrBlkVcSe/0qlZag1f3WaDkWyoj8E/u3APUYotQXnCEDc5GGxz9KgkKs2EVwpYbd3pVsCO1fEFw0xBBXsff8QaaEnb5m1AiW1tJHfKvkjIV2GGVh29xmq9vJblftSwomxdrgsckkfw+lZUe+5uXLPlsEsXJw3v8AWtSPyDZorRyRlx5gb+9jgY9BV/EZOPIrN6sqLM9zEsbMzKq7QT1IB6/WrAijyI0Zoos7SzEkDHrUGya0kEifvip+fK7l5qYXHyGFocFDmRlOcjPp+lZpX3NX0sIm5JQC4WQHnA6j/CtAxtE0k2yN4mb+HBPXqRUAHnqZY4yFUA528L6VeggSVmU3AQqvzBT94njGP6UKOpM5LqNuRGs8cQCOC3zHGMA+/XFXoWHlvFBEywMuSqcEN/F17YxVDzY4smIP5rH512noOo568AdK1JYrm8uFCxhbcbefug+oPrmtUrmUmrK4kcf2e4itLibCqgIfdkdcg/lV5bcNK5j8sSO5AZweQec5qpLHFp8jbl+0FjsCryuD2PpWjDLvh8tYDFHksvOCw9vQ1Sj3MZyas0RzWsMLI17M2F/5ZoMdulW43ciNI49u77i54GO/PJpkESMfI3PIdvG58n64pEmbjy1zhgdzD5iM+p4poyd3uX4hI8sWyVFjVdrsepPrmpkjtFLBHkZ3Oc7eCfTntVcTCNn8tI4S7DOeQfw9agedd5LI85clgW4A/wAMVRlytk00aSzpH/qmZtu3PBA6/Sq1wyXFw0sksXlop2oAT8o4z+dNmuw1u++QgNyVUgHHrUaLAyh2MjJgEbsjd6f1qXq7GihbVlSWJjFI3mM2GwoRdo56nNKpEatIoeU24KdOrtxx60y9kFx+5iRhKxBDZITHoaWNWlZ2QKPLYyM57Y6Y7c8daSR0W0uVJodqRQqjO6nJHC/N3p8LRac6PdAS3AVm2c8HoB7D3qnd3EqMhAYOctv6kMfp/KkRwzuSsfl8s8jEklv7369KSa2saOLas9hkfnTw/aLwxtH8ywws2FTAyT9O/vUqhFBebEYGCoUHczYxwPSpJLhLWN7OKETLE+WWXBJ4/QVmeZcuN8kqmS5JZsN9xFPCg44/rT2aQ1Fy20Q5ilzI0su6HS0xkfxSew+tQ6heS3e63DCARgswzjYvQKMdT61HcuBFGi7hGPmRcfff1PsKoRTIkiFVDOHJOB99u315qXLojaFPr2J0gkSf7OsebogMsS/MI/Un3q26yKQB5cFooEeTjcxP3jjt1piXK6fGYC5+2TEh8DcU65/PNUIZRb28waLZKVHlFs4Cn+Ij8OPrSTSJkpTd1/w4y63zOBE+2NmO1j37VNbwQ2z2+GaOQfMR/cHoPU1BFcs0u5Q5woOSMDjsKtaXbCUvcTSBMMuF/vdwoP8AOnFXJqvljZ6CIJbTQprqT91G8wyVA3Ac9++axXljdJHLO7ucRgj7oHf8qtajNf6vObdEcxo5/dheAxP9Klj06DTAZru5Xz9xURR4bB9DTbbl5GUXGCvJ6sxJCpWYNHyWySDggU24WRovJty5aTC4J7Y5Bqe6mhMrMsu5d3zvt4HpWfcXjllifJQESZHB46VKSWhUm3qZN7bTW87RhMtnacjgVm3EkkEojizvxzg5rc+0y3E0000iAS87BwAc1lzREzzy7drrgVSiuhlOpf4iC4lwiZLHYNzAdjWHcSSTPtAw3JJrVvJzE4BA+YZOa5PVtaFl5qptaZuPpW8I2PNq1LGH4lvBNOIgfu8EVhPnacZ/CnSSF5GdurHNMY56V0JWPPbuzutY1SfS5bSJbS1ufDE8KCKAIu2UbRvO7qJASefWoNR0+Gy8F38thOLjT7m9gkt5MjcBtbKOOzDofXrXN6fpN/qERezt3khU4LlgqA+mWIGfpUF9bXVjM1vdxSwSHDFG4Deh9D9akdyIdKKjyfU0VV2IQUqkDOaZj3NLu5xTAkOc04dKjVsZzUlABSE4xS0jY7igDrPCFwvlMmcYNd1od1tkWMdc85NeU+Hbgx3irzhuPxrvtLlCSIfxzXDWXv6HpYWV42Z17ytHdBxgY61NZziWZ3BPlk1nsTOqscjt161MIjCwEf389M4FZa7nZFlm8ge2nBIIVhlGx1FPWUvgZBAHNWmLXNjslc8cAehrKt5WEzAY465qZxUXp1N6c3LVmijEbWzyBmrKyAkYJIPr1rO8xpHweMdqnhfYwYdelZbHVHVamnG42gKCH9c9easXcxneORlXeBjjrx61QikHzbycbu3WppHaOUpJ99OuP51Vh9S15qOgJLBlxj3x2qzbyIJgTGzKSMhT3+tUbd2MUkqYJUjt0qeGYghovkBHP+96j3px7D8jWWxnuIReiRNruRtY4IQfzpxeaYKJXI8oEKSOimsqHzQkigsH77W49c1PHC0tpxIySK3Pcsh/GrTJ5bfEzcsVubcArJC4lOAuSNw65q/ewShdQeKZWhGCXEfTHIyfrxWJDZMqQlLxm3vsAKkFRxnmrkkUWl+Z5srSiXlI1ZtpHbd61aS7aGEknK6evoS7ZeDPcghlDunGGHXafU0IlnAUZpvMBb5lVcEjv9D/AIVSs9sLySIxKldyh+QM9PypUuLVGZnLtAPlcpw34ZpLY1UXrZm1DO4uy0fEmzzYzJyG4yB+IqzanUL+MzThFh2ZOTtwPUjqayZb9Y7aARRgZRih/iUA9M9xVmPzNQBa6kYSMoKHqAT1H0pp2IlDS+xfgnSwybdjPOAN27gYz2FWy1w2WuJTDuPyAp1Oc9KqwW8kNojWjmZyp+/gbSDjH4daozTv58EmoTNI8nAUDkL0z6Ve2hnGCm7xNqa8tobhpMn5gF3BduOefxqc3loIykUTuykgMVI6/XjmssXUsV6sEmd7x+YsgAOOPQ+tWrdrhoY5QqKRzudixJ+nTHNNN7EOCSTLaSh1kcWyCVQQNzfMPTGOaZdtfFR9owDjG0DGTSRsWyIpA0mCHTGABj6etVGeIIblwxfcFZixOT1Ix6YFD2Jile9iWbHmRhoxEhO58HJkx3AqG9M/n+bPFIVZsRlZAduR6GkjvoJlMklwVi+6uIgfepPtj3Iljjt2eMH5Wkl/oOlSlfqaJNdCHz4IpT/pLL5ZJIDbst/dz0qKeWVreZVVVjQ7pcg5OcbVBqKQzzTw24wHBCqqKFUH1z1qO+RbS3eS5mJmaQ7SATnH6daXS5oop2uRXMwRzHGqRbCCZdmNuTyB/jS+YhujOJDDb5wocbmf3A759Krp5hM0twNxCkv82Tt449KqtNLPeee0ojSFS0jqv3PRUH9am5ryLVGgLl7mC4js4xDK7HL/ANxe5LH+I+lRXF5Y2xVpA92ZCA+9scDqeOMe1QQBb+G3ggjMULne4LcsR0JPqaoa8DJeuNoUAbQR/d6Dj8KG7K6HThGU+V7FbUL6S/vy2VyTgY6Ko6AfSr+nxra2637L8quREB1B7tj6msyEpHtZ1wjHc7D7zew9qkimNxPKqBYkK4VMHt0H4nrURdtWdFVe7yx0Bv3TySPukndiEX0z/EasSZCtJcYknYYyTnYo6n60gilsJpHkKNcrjahGQcg5Ofai0ge9DbyJXU5fdwpPbPfirSvoc85JK/Ql0mz+2YfeBCRsChgG9857mrE5EKCfUQI4LUbYLNTnb6Fz3NYcE89/epZtMIoIWaRmRey98dzT0uZbp9wH7k/cDc8f496qGq0OepBt6vQ0v7duo7Vv3SwXNy2RtGPl9aw5YpUEaySjZIdzAnkD+dO+YXK5b945OM/wgVjXV6ZJnDkHJG845xRJ23FTgk/d0LN75KxmeOP92zEKuTlv9oisp3F0VVGwGHzhR09BTzqUoBSEAxjIUE029nMpVLBFWRU3SMeOfWkmnqhVG4qxVdUaQYYAL0X1NZ93KqF5WfJDcgdM1YjvgkCGVB5mccVnahelrd08hVB963grnnVZSW5j+Ir1UhM0j5kHTb0rzi5naeZpJDktWt4k1ETymEZG3g1gkjGa3Uep5s5NsXmjt6e/pTWPp2o/GqJOz8S2Mk9m8VnaS3H2ScQRrHlvIhCKVIQf89CSxb2xUfiGFV0OSOSIwG38h1hLFvs8kgbfECeQCFVtvasqy1zZHFHe2ouTCnlxSpM0Mip/dLL94emelVtT1N71I4kijt7SIlkhjyRuPVmJ5Zj6mkkO5Qopu4UVZJ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Total destruction of the nail with a ridged, hyperkeratotic nail bed is present in this patient with totally dystrophic onychomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4148=[""].join("\n");
var outline_f4_3_4148=null;
var title_f4_3_4149="Glabellar rhytides at rest and contraction";
var content_f4_3_4149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glabellar rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical lines consistent with glabellar rhytides are present between the eyebrows. This patient has rhytides that are visible at rest (top). The rhytides are more prominent when she attempts a strong frown (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4149=[""].join("\n");
var outline_f4_3_4149=null;
var title_f4_3_4150="Food allergy oral tolerance";
var content_f4_3_4150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Mechanisms of oral tolerance: Antigen dose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 635px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oral tolerance is mediated through different mechanisms, depending upon the antigen dose. A, Low doses of ingested antigen induce tolerance via activation of regulatory T cells that produce suppressive cytokines, such as IL-10 and TGF-beta. B. High doses of oral antigen lead to induction of tolerance via anergy (TCR cross-linking occurs without costimulation) or deletion (TCR is cross-linked in the presence of inhibitory molecules, CD95 and CD95L, leading to FAS-mediated apoptosis).",
"    <div class=\"footnotes\">",
"     L: ligand; R: receptor; TCR: T cell receptor",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Chehade, M, Mayer, L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115:3. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2005 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4150=[""].join("\n");
var outline_f4_3_4150=null;
var title_f4_3_4151="Target cells";
var content_f4_3_4151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Target cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear shows multiple target cells which have an area of central density surrounded by a halo of pallor (arrows). These cells are characteristic of liver disease and certain hemoglobinopathies (most notably hemoglobin C disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4151=[""].join("\n");
var outline_f4_3_4151=null;
var title_f4_3_4152="Vinblastine: Drug information";
var content_f4_3_4152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vinblastine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17349?source=see_link\">",
"    see \"Vinblastine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=see_link\">",
"    see \"Vinblastine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16369039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vinblastine Sulphate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Vinca Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Frequency and duration of therapy may vary by indication, concomitant combination chemotherapy and hematologic response.",
"     <b>",
"      For I.V. use only.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antineoplastic (typical dosages):",
"     </b>",
"     I.V.: Initial: 3.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; adjust dose every 7 days (based on white blood cell response) up to 5.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (second dose); 7.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (third dose); 9.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (fourth dose); and 11.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (fifth dose); do not administer more frequently than every 7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual range: 5.5-7.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days; Maximum dose: 18.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; dosage adjustment goal is to reduce white blood cell count to ~3000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hodgkin&rsquo;s disease:",
"     </i>",
"     Usual dose: 6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (as part of a combination chemotherapy regimen) (Bartlett, 1995; Horning, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Testicular cancer:",
"     </i>",
"     Usual dose: 0.11 mg/kg daily for 2 days every 3 weeks (as part of a combination chemotherapy regimen) (Loehrer, 1998)",
"     <b>",
"      or",
"     </b>",
"     6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days every 3-4 weeks (as part of a combination chemotherapy regimen) (Clemm, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Bladder cancer (unlabeled use):",
"     </i>",
"     Usual dose: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days for 3 out of 4 weeks (as part of combination chemotherapy) (Sternberg, 2001)",
"     <b>",
"      or",
"     </b>",
"     3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 2, 15, and 22 of a 28-day treatment cycle (as part of a combination chemotherapy regimen) (von der Maase, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Melanoma (unlabeled used):",
"     </i>",
"     2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1-4 and 22-25 of a 6-week treatment cycle (as part of a combination chemotherapy regimen) (Eton, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nonsmall cell lung cancer (unlabeled use):",
"     </i>",
"     4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, 15, 22, and 29, then every 2 weeks (as part of combination chemotherapy) (Arriagada, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ovarian cancer (unlabeled use):",
"     </i>",
"     0.11 mg/kg daily for 2 days every 3 weeks (as part of a combination chemotherapy regimen) (Loehrer, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=see_link\">",
"      see \"Vinblastine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Frequency and duration of therapy may vary by indication, concomitant combination chemotherapy and hematologic response.",
"     <b>",
"      For I.V. use only.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin&rsquo;s disease:",
"     </b>",
"     I.V.: Initial dose: 6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; do not administer more frequently than every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Letterer-Siwe disease:",
"     </b>",
"     I.V.: Initial dose: 6.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; do not administer more frequently than every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer:",
"     </b>",
"     I.V.: Initial dose: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; do not administer more frequently than every 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F234104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     According to FDA-approved labeling, no adjustment is necessary in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The FDA-approved labeling recommends the following guidelines: Serum bilirubin &gt;3 mg/dL: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;3.1 or transaminases &gt;3 times ULN: Avoid use (Floyd, 2006)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 1.5-3 mg/dL or AST 60-180 units: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 3-5 mg/dL: Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;5 mg/dL or AST &gt;180 units: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sulfate: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      FATAL IF GIVEN INTRATHECALLY",
"     </b>",
"     . For I.V. administration only, usually as a slow (2-3 minutes) push, or a bolus (5-15 minutes) infusion; the manufacturer recommends an undiluted 1-minute infusion to prevent venous irritation/extravasation. Prolonged administration times and/or increased administration volumes may the risk of vein irritation and extravasation. Assure proper needle or catheter placement prior to administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bleomycin, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, gemcitabine, granisetron, heparin, leucovorin calcium, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, paclitaxel, pemetrexed, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, furosemide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxorubicin, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin's and non-Hodgkin's lymphoma; testicular cancer; breast cancer; mycosis fungoides; Kaposi's sarcoma; histiocytosis (Letterer-Siwe disease); choriocarcinoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6753820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder cancer, melanoma, nonsmall cell lung cancer (NSCLC), ovarian cancer, soft tissue sarcoma (desmoid tumors)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       VinBLAStine may be confused with vinCRIStine, vinorelbine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Must be dispensed in overwrap which bears the statement",
"       <b>",
"        \"Do not remove covering until the moment of injection. Fatal if given intrathecally. For I.V. use only.\"",
"       </b>",
"       Syringes should be labeled:",
"       <b>",
"        \"Fatal if given intrathecally. For I.V. use only.\"",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Common:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, leukopenia/granulocytopenia (nadir: 5-10 days; recovery: 7-14 days; dose-limiting toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, jaw pain, tumor pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Less common:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, cerebrovascular accident, coronary ischemia, ECG abnormalities, limb ischemia, MI, myocardial ischemia, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, neurotoxicity (duration: &gt;24 hours), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, photosensitivity (rare), rash, skin blistering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Aspermia, hyperuricemia, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, gastrointestinal bleeding, hemorrhagic enterocolitis, ileus, metallic taste, nausea (mild), paralytic ileus, rectal bleeding, stomatitis, toxic megacolon, vomiting (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, thrombocytopenia (recovery within a few days), thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Cellulitis (with extravasation), irritation, phlebitis (with extravasation), radiation recall",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Deep tendon reflex loss, myalgia, paresthesia, peripheral neuritis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Auditory damage, deafness, vestibular damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hemolytic uremic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pharyngitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Significant granulocytopenia; presence of bacterial infection; I.T. administration is contraindicated (may result in death)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Leukopenia is common; granulocytopenia may be severe with higher doses. Leukopenia may be more pronounced in cachectic patients and patients with skin ulceration. Thrombocytopenia and anemia may occur rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: May rarely cause disabling neurotoxicity; usually reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; toxicity may be increased; may require dosage modification.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic heart disease: Use with caution in patients with ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Itraconazole: Itraconazole may decrease the metabolism of vinblastine via CYP3A4 inhibition and may increase the effects of vinblastine via P-glycoprotein effects. Severe myelosuppression and neurotoxicity may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mitomycin: Acute shortness of breath and severe bronchospasm have been reported, most often in association with concurrent administration of mitomycin; may occur within minutes to several hours following vinblastine administration or up to 14 days following mitomycin administration; use caution in patients with pre-existing pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Avoid eye contamination (exposure may cause severe irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NOT for intrathecal use:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. use only.",
"     </b>",
"     <b>",
"      Intrathecal administration may result in death.",
"     </b>",
"     Must be dispensed in overwrap which bears the statement",
"     <b>",
"      \"Do not remove covering until the moment of injection. Fatal if given intrathecally. For I.V. use only.\"",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vesicant:",
"     <b>",
"      [U.S. Boxed Warning]: Vinblastine is a moderate vesicant; avoid extravasation. Individuals administering should be experienced in vinblastine administration.",
"     </b>",
"     Assure proper needle or catheter placement prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of VinBLAStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: VinBLAStine may increase the serum concentration of Tolterodine.  Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease vinblastine levels). Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6753821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated resorption and teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant during vinblastine treatment. Aspermia has been reported in males who have received treatment with vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6753863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VinBLAStine Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (10 mL): $31.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (VinBLAStine Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $16.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum uric acid, hepatic function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Blastovin (IL, PY);",
"     </li>",
"     <li>",
"      Cytoblastin (BG, IN);",
"     </li>",
"     <li>",
"      Lemblastine (MX);",
"     </li>",
"     <li>",
"      Oncoblastin (CO, PE);",
"     </li>",
"     <li>",
"      Oncostin (PH);",
"     </li>",
"     <li>",
"      Velban (BR);",
"     </li>",
"     <li>",
"      Velbastine (HK, PH, SG);",
"     </li>",
"     <li>",
"      Velbe (AR, AT, AU, BE, BF, BJ, CH, CI, CN, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HN, HR, IE, IT, KE, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, PK, PL, PT, RU, SC, SD, SE, SK, SL, SN, TN, TR, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Vinblastin (HU, PL);",
"     </li>",
"     <li>",
"      Vinblastine Sulfate Injection (AU);",
"     </li>",
"     <li>",
"      Xintoprost (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vinblastine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinblastine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 27.3 L/kg; binds extensively to tissues; does not penetrate CNS or other fatty tissues; distributes to liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 4 minutes; Terminal: 25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (95%); urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arriagada R, Bergman B, Dunant A, et al, &ldquo;Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(4):351-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/14736927/pubmed\" id=\"14736927\" target=\"_blank\">",
"        14736927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartlett NL, Rosenberg SA, Hoppe RT, et al, &ldquo;Brief Chemotherapy, Stanford V, and Adjuvant Radiotherapy for Bulky or Advanced-Stage Hodgkin&rsquo;s Disease: A Preliminary Report,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(5):1080-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/ 7537796/pubmed\" id=\" 7537796\" target=\"_blank\">",
"        7537796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bashir H, Motl S, Metzger ML, et al, &ldquo;Itraconazole-Enhanced Chemotherapy Toxicity in a Patient With Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2006, 28(1):33-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/16394890/pubmed\" id=\"16394890\" target=\"_blank\">",
"        16394890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonadonna G, Valagussa P, and Santoro A, &ldquo;Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1986, 104(6):739-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/2422994/pubmed\" id=\"2422994\" target=\"_blank\">",
"        2422994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chong CD, Logothetis CJ, Savaraj N, et al, &ldquo;The Correlation of Vinblastine Pharmacokinetics to Toxicity in Testicular Cancer Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1998, 28(8):714-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/3216038/pubmed\" id=\"3216038\" target=\"_blank\">",
"        3216038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clemm C, Hartenstein R, Willich N, et al, &ldquo;Vinblastine-Ifosfamide-Cisplatin Treatment of Bulky Seminoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1986, 58(10):2203-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/3756768/pubmed\" id=\"3756768\" target=\"_blank\">",
"        3756768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(8):2045-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/11956264/pubmed\" id=\"11956264\" target=\"_blank\">",
"        11956264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman M, Venkatesan TK, and Caldarelli DD, &ldquo;Intralesional Vinblastine for Treating AIDS-Associated Kaposi's Sarcoma of the Oropharynx and Larynx,&rdquo;",
"      <i>",
"       Ann Otol Rhinol Laryngol",
"      </i>",
"      , 1996, 105(4):272-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/8604887/pubmed\" id=\"8604887\" target=\"_blank\">",
"        8604887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Hoppe RT, Breslin S, et al, &ldquo;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/11821442/pubmed\" id=\"11821442\" target=\"_blank\">",
"        11821442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loehrer PJ Sr, Gonin R, Nichols CR, et al, &ldquo;Vinblastine Plus Ifosfamide Plus Cisplatin as Initial Salvage Therapy in Recurrent Germ Cell Tumor,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(7):2500-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/9667270/pubmed\" id=\"9667270\" target=\"_blank\">",
"        9667270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pronzato P, Queirolo P, Vidili MG, et al, &ldquo;Continuous Venous Infusion of Vinblastine in Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Chemotherapy",
"      </i>",
"      , 1991, 37(2):146-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/2032471/pubmed\" id=\"2032471\" target=\"_blank\">",
"        2032471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sternberg CN, de Mulder PH, Schornagel JH, et al, &ldquo;Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic M-VAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(10):2638-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/11352955/pubmed\" id=\"11352955\" target=\"_blank\">",
"        11352955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Maase H, Hansen SW, Roberts JT, et al, &ldquo;Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(17):3068-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/11001674/pubmed\" id=\"11001674\" target=\"_blank\">",
"        11001674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams SD, Birch R, Einhorn LH, et al, &ldquo;Treatment of Disseminated Germ-Cell Tumors With Cisplatin, Bleomycin, and Either Vinblastine or Etoposide,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1987, 316(23):1435-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/3/4152/abstract-text/2437455/pubmed\" id=\"2437455\" target=\"_blank\">",
"        2437455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10044 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-ACD0464BDC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4152=[""].join("\n");
var outline_f4_3_4152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708853\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369039\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234144\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234102\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234123\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234103\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234104\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234105\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234064\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234082\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234150\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234080\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6753820\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234153\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234142\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234085\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234068\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234139\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234073\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234096\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234075\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6753821\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6753863\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324092\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234077\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234088\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234067\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234084\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17349?source=related_link\">",
"      Vinblastine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=related_link\">",
"      Vinblastine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_3_4153="Bronchial carcinoid tumors: Treatment and prognosis";
var content_f4_3_4153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchial carcinoid tumors: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Charles F Thomas, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4153/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4153/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/3/4153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1143202982\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial neuroendocrine (carcinoid) tumors are a rare group of pulmonary neoplasms that are characterized by neuroendocrine differentiation and relatively indolent clinical behavior. Although originally referred to as bronchial adenomas, these tumors are now recognized as malignant neoplasms because of their potential to metastasize.",
"   </p>",
"   <p>",
"    Like other carcinoid tumors, bronchial carcinoids are thought to derive from peptide- and amine-producing neuroendocrine cells that have migrated from the embryologic neural crest. Carcinoids can arise at a number of sites throughout the body, including the thymus, lung, gastrointestinal tract, and ovary. The gastrointestinal tract is the most frequently involved site, while lung is the second most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, bronchial carcinoids are part of a spectrum of neuroendocrine tumors arising in the lung that are characterized by strikingly different biologic behavior. At one end of the spectrum are typical carcinoids, which are low-grade (well-differentiated), slowly-growing neoplasms that seldom metastasize to extrathoracic structures. At the other end of the spectrum are the high-grade (poorly differentiated) neuroendocrine carcinomas, as typified by small cell lung cancer (SCLC), which behave aggressively, with rapid tumor growth and early distant dissemination. The biologic behavior of atypical carcinoids, which are intermediate-grade tumors with a higher mitotic rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis, is intermediate between typical carcinoids and SCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H5#H5\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Classification, histology, and histochemistry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prognosis of both typical and atypical bronchial carcinoid tumors will be discussed here. The epidemiology, classification, clinical features, diagnosis, and staging of bronchial carcinoid tumors is discussed elsewhere, as is treatment of well-differentiated carcinoid tumors arising in other sites and poorly differentiated neuroendocrine cancers arising in the lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=see_link\">",
"     \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201164\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with typical or atypical bronchial carcinoid tumors, surgical resection is the preferred treatment approach for patients whose overall medical condition and pulmonary reserve will tolerate it. For patients whose condition does not permit complete resection and for exceptional cases where the lesion is entirely intraluminal, bronchoscopic resection may be an alternative. (See",
"    <a class=\"local\" href=\"#H1143201199\">",
"     'Endobronchial management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201171\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for carcinoid tumors and the only therapeutic option offering the best chance of cure. The goal is en bloc resection of the entire neoplasm with preservation of as much functional lung as possible. Attempts to preserve lung parenchyma by the use of bronchoplastic techniques (eg, sleeve, wedge, or flap resection) to avoid lobectomy, bilobectomy, or pneumonectomy are justified and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since carcinoids, unlike bronchogenic carcinomas, tend not to spread submucosally, a surgical margin as narrow as 5 mm is considered adequate. Intraoperative frozen section analysis is critical to the success of this approach. Although long-term survival has been reported in patients with positive margins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/2,4\">",
"     2,4",
"    </a>",
"    ], repeat surgery with wider resections is preferred if there are positive margins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7045450\">",
"    <span class=\"h3\">",
"     Proximal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For polypoid tumors of the main-stem bronchus or bronchus intermedius, a simple bronchotomy with wedge or sleeve resection of the bronchial wall and complete preservation of distal lung parenchyma could be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/6\">",
"     6",
"    </a>",
"    ]. However, such completely parenchyma-sparing procedures are only rarely possible because of the frequency of \"iceberg\" lesions (in which the tumor appears entirely intraluminal bronchoscopically but has a significant extraluminal component that is evident with high-resolution CT scanning). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H18#H18\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Cross sectional imaging'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Tumors with more extensive central involvement, those that are associated with severe distal parenchymal disease (ie, nonfunctioning lung parenchyma), and atypical carcinoids require more extensive surgery (eg, lobectomy or pneumonectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7045461\">",
"    <span class=\"h3\">",
"     Peripheral tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For peripheral lesions, the ideal surgical approach is debated, and there is no consensus. Segmental sleeve resections are associated with a greater risk of postoperative stenosis compared with bronchoplastic procedures in wider bronchial segments. This has led some to advocate lobectomy in the case of a tumor involving the orifice of a segmental bronchus, while others suggest that a more limited resection (eg, wedge resection or segmentectomy) is appropriate for typical carcinoids because of the low likelihood of a local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7045468\">",
"    <span class=\"h3\">",
"     Role of lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 5 and 20 percent of typical carcinoids and 30 to 70 percent of atypical carcinoids metastasize to lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/8\">",
"     8",
"    </a>",
"    ]. A complete mediastinal lymph node sampling or dissection at the time of initial treatment is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], with surgical resection of nodal metastasis whenever feasible. Metastatic involvement of mediastinal lymph nodes does not preclude a full surgical resection or cure. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201178\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7045482\">",
"    <span class=\"h4\">",
"     Typical carcinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical bronchial carcinoids have an excellent prognosis following surgical resection. Reported five-year survival rates are 87 to 100 percent; the corresponding rates at 10 years are 82 to 87 percent (",
"    <a class=\"graphic graphic_table graphicRef56644 \" href=\"UTD.htm?9/63/10237\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/7,8,11-19\">",
"     7,8,11-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic impact of nodal involvement for typical bronchial carcinoids is controversial. Some studies show a worse outcome compared to cases without nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], while many do not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Incomplete resection is the only widely accepted feature associated with negative prognostic significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7045475\">",
"    <span class=\"h4\">",
"     Atypical carcinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical carcinoids have a greater tendency to metastasize (16 and 23 percent in two large series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]) and to recur locally (3 and 23 percent in the same two series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]). Five-year survival rates range widely from 30 to 95 percent; the corresponding rates at 10 years are 35 to 56 percent (",
"    <a class=\"graphic graphic_table graphicRef56644 \" href=\"UTD.htm?9/63/10237\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/8,12,15,17,18,21,23,26-30\">",
"     8,12,15,17,18,21,23,26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to typical carcinoids, most series report an adverse influence of nodal metastases on prognosis for patients with atypical carcinoid (",
"    <a class=\"graphic graphic_table graphicRef56644 \" href=\"UTD.htm?9/63/10237\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/14,17,25,27,31\">",
"     14,17,25,27,31",
"    </a>",
"    ]. This is best illustrated by the experience at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/14\">",
"     14",
"    </a>",
"    ]. Nineteen of 23 patients with typical bronchial carcinoids and lymph node involvement (83 percent) remained alive and well, while four failed distantly, two of whom died. In contrast, only 4 of the 11 patients with atypical tumors and lymph node involvement were alive without disease, while seven developed distant metastases and six died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201185\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant therapy after complete resection of a bronchial carcinoid is undefined, and we do not suggest its use for either atypical or typical carcinoid tumors, regardless of stage. Others, including the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , recommend the use of adjuvant therapy for selected patients with atypical carcinoid, largely based upon retrospective literature reports suggesting benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/13,32-36\">",
"     13,32-36",
"    </a>",
"    ]. However, many of the series that purport to show a benefit for adjuvant therapy included patients with large cell neuroendocrine tumors whose outcome is significantly worse than that of patients with atypical carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/17\">",
"     17",
"    </a>",
"    ]. The role of chemotherapy and radiation in the setting of small cell and large cell neuroendocrine lung cancers is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no prospective trials that directly address the benefit of adjuvant therapy for patients with bronchial carcinoids (typical or atypical), and there is only scant experience from a single-institution retrospective series that are limited to patients with typical and atypical carcinoid tumors. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from Sloan Kettering Cancer Center included 25 patients with node-positive disease (12 typical and 13 atypical carcinoids) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/24\">",
"       24",
"      </a>",
"      ]. Nine of the 15 patients with N2 disease received adjuvant RT. The five-year overall survival rate was 75 percent, and it was not better in those who received adjuvant RT. The use of RT also did not influence the failure pattern; most recurrences were distant and correlated with cell type.",
"     </li>",
"     <li>",
"      MD Anderson reported their experience in 73 surgical patients with bronchial carcinoids, seven of whom received adjuvant RT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy because of positive margins, local invasion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph node involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/36\">",
"       36",
"      </a>",
"      ]. Only one of the seven patients who underwent surgery followed by RT was alive without evidence of disease 10 years later.",
"     </li>",
"     <li>",
"      In an Italian series of 42 patients with pulmonary carcinoids (26 typical, 16 atypical), RT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic therapy (four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) was administered to all seven patients with stage III disease and to one patient who had a T3N1 tumor as assessed by the older 6",
"      <sup>",
"       th",
"      </sup>",
"      edition of the AJCC staging system [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/13\">",
"       13",
"      </a>",
"      ]. Despite the use of adjuvant therapy, five of the seven patients who had received adjuvant therapy recurred and died of their disease, all of whom had atypical histology. Among the four patients who recurred after systemic chemotherapy, all failed with distant disease, none locally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the lack of data and uncertainty as to benefit, we do not routinely recommend adjuvant therapy for completely resected typical or atypical carcinoids, with or without regional nodal involvement. Radiation therapy is a reasonable option for atypical carcinoids if gross residual disease remains after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/32\">",
"     32",
"    </a>",
"    ], although whether this improves outcomes is unproven.",
"   </p>",
"   <p>",
"    This recommendation is consistent with consensus-based guidelines from the North American Neuroendocrine Tumor Society (NANETs) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/9\">",
"     9",
"    </a>",
"    ], but not with those of the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , which suggest the use of chemotherapy with or without radiation therapy for resected stage II or III (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 2",
"    </a>",
"    ) atypical carcinoids and for stage IIIB typical carcinoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201199\">",
"    <span class=\"h2\">",
"     Endobronchial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with a suspected central bronchial carcinoid tumor, bronchoscopy is the procedure of choice to obtain a preoperative histologic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H17350455#H17350455\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Bronchoscopy and biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14397458\">",
"    <span class=\"h3\">",
"     Endobronchial resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, a polypoid tumor may appear entirely intraluminal and amenable to bronchoscopic resection. For highly selected patients with a central polypoid bronchial carcinoid, bronchoscopic resection with a Nd:YAG laser alone may provide prolonged recurrence-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/15,21,37,38\">",
"     15,21,37,38",
"    </a>",
"    ]. In the largest series of 72 patients treated with this approach (57 typical and 15 atypical carcinoids), initial bronchoscopic management resulted in complete tumor eradication in 33 (46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/37\">",
"     37",
"    </a>",
"    ]. Surgery was required in 37 (including 11 of the 15 atypical carcinoids), two for delayed recurrences at 9 and 10 years. At a median follow-up of 65 months, 66 (92 percent) remained alive, and only one of the deaths was tumor-related.",
"   </p>",
"   <p>",
"    Close posttreatment follow-up is an integral component of bronchoscopic resection. In the series described above, patients underwent high-resolution CT and flexible bronchoscopy with bronchoscopic ultrasonography within six weeks after endobronchial resection and referred for surgery for any evidence of residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/37\">",
"     37",
"    </a>",
"    ]. Repeat evaluation was performed every six months for two years and annually thereafter.",
"    <br/>",
"    <br/>",
"    In general, the most appropriate candidates for endobronchial resection are patients who present with a polypoid intraluminal tumor, who have good bronchoscopic visualization of the distal tumor margin, and no evidence of bronchial wall involvement or suspicious lymphadenopathy by high resolution CT.",
"   </p>",
"   <p>",
"    However, we do not consider that bronchoscopic resection represents a standard potentially curative treatment for the vast majority of patients with central lesions because even in the setting of a negative CT, most tumors extend into or through the wall of the bronchus, and endobronchial resection risks leaving substantial tumor behind either within or beyond the endobronchial lumen. Because of the slow growing nature of carcinoid tumors, it may take years before a recurrence develops. Until more data are available, bronchoscopic laser resection is best reserved for palliative treatment of patients with central airway occlusion who are poor surgical candidates (eg, elderly, debilitated) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Laser therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser bronchoscopic removal of an obstructing lesion may also be useful preoperatively to allow the surgeon to plan the most appropriate surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14397465\">",
"    <span class=\"h3\">",
"     Endobronchial cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of bronchoscopic cryotherapy was addressed in a small series of 18 isolated endoluminal typical bronchial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/43\">",
"     43",
"    </a>",
"    ]. There was only a single recurrence seven years after initial treatment, and the procedure was safe and not associated with later development of bronchial stenosis. As with endobronchial laser resection, this procedure is best reserved for palliative management of patients with central airway occlusion who are poor surgical candidates (eg, elderly, debilitated).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201213\">",
"    <span class=\"h2\">",
"     Locally advanced unresectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although carcinoid tumors have been considered relatively radiation-resistant, definitive radiation therapy (RT) can provide effective palliation of a locally unresectable primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/32,44\">",
"     32,44",
"    </a>",
"    ]. It is not a curative option, however.",
"   </p>",
"   <p>",
"    Some recommend that patients with locally advanced unresectable pulmonary carcinoids undergo chemotherapy plus RT, in a manner similar to treatment for intrathoracic small cell lung cancer (SCLC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/45\">",
"     45",
"    </a>",
"    ]. However, response rates seem to be lower than are seen with SCLC, and whether this approach is superior to RT alone remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201220\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite their low malignant potential, long-term follow-up of patients with bronchial carcinoids is warranted because local or distant disease recurrence may occur many years after initial treatment.",
"   </p>",
"   <p>",
"    The optimal posttreatment surveillance strategy is not defined, and there is no consensus on what tests should be ordered. We perform history and physical examination and chest CT annually for patients with resected typical carcinoid and every six months for resected atypical carcinoids for the first two years, then annually. These recommendations are consistent with those suggested by NANETS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/9\">",
"     9",
"    </a>",
"    ]; guidelines for posttreatment surveillance for bronchial carcinoids are not available from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although some authors recommend somatostatin receptor scintigraphy (SRS) in the follow-up of patients with bronchial carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/46\">",
"     46",
"    </a>",
"    ], we do not routinely order SRS unless there is suspicion for metastatic disease. Similarly, measurement of serum levels of chromogranin A (CgA) can be useful to follow disease activity in the setting of advanced or metastatic disease, but we do not routinely monitor CgA levels postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H22#H22\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Other imaging procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H11#H11\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Clinical syndromes related to peptide production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201227\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT OF METASTATIC CARCINOID AND THE CARCINOID SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent site of metastatic disease is the liver; other sites include bone, adrenal glands, and brain. The rarity of bronchial carcinoids has prevented the design of prospective trials, and few data are available regarding treatment for relapsed or advanced disease. In most cases, treatment principles are extrapolated from the experience with the more common gastrointestinal (GI) carcinoids. However, even among patients with GI tract carcinoids, the optimal management of these patients, particularly in the setting of advanced unresectable disease, is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201234\">",
"    <span class=\"h2\">",
"     Liver-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the predominant site of metastatic disease. Hepatic resection is indicated for the treatment of selected patients with isolated, limited volume, metastatic liver disease. Although the majority of cases will not be cured by surgery, symptoms of hormone hypersecretion are effectively palliated, and prolonged survival is often possible, given the slow-growing nature of these tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691398#H691398\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic predominant metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other liver-directed therapies for hepatic-predominant disease include hepatic artery embolization and chemoembolization, radiofrequency ablation, and cryoablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691441#H691441\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Nonsurgical liver-directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201241\">",
"    <span class=\"h2\">",
"     Somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of symptoms caused by secretion of biologically active amines or peptides may be achieved in 60 percent of cases by somatostatin receptor analogs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (or where available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    ). Although these drugs can also slow tumor growth and provide for prolonged periods of disease stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/47\">",
"     47",
"    </a>",
"    ], radiographic regression of disease is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=see_link&amp;anchor=H624742796#H624742796\">",
"     \"Treatment of the carcinoid syndrome\", section on 'Somatostatin-analog therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201248\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, carcinoid tumors have been considered relatively radiation-resistant. However, radiation can provide useful pain relief for patients with bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/44,48\">",
"     44,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201255\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For metastatic carcinoid tumors as a group, multiple cytotoxic drugs have been tried in various combinations, but randomized trials have revealed only minor activity. As a result, there is no standard regimen, and the role of chemotherapy for advanced carcinoid tumors in general continues to be debated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948991#H190948991\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some data to suggest that bronchial carcinoids have somewhat different chemotherapy sensitivity compared to carcinoids originating at other sites, although the reasons why this should be so are unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with metastatic disease from bronchial carcinoid are often treated with regimens that are typically used for SCLC. Although chemotherapy responsiveness is not as predictable as it is with SCLC, objective partial responses have been documented using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some data suggest activity with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      . A retrospective study of patients with metastatic or inoperable malignant neuroendocrine tumors included 13 bronchial carcinoids (10 typical and three atypical); all received oral temozolomide for five consecutive days every 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/51\">",
"       51",
"      </a>",
"      ]. Four (31 percent) had a partial response, and four others had stable disease.",
"      <br/>",
"      <br/>",
"      Although these results seem promising, activity for temozolomide monotherapy in bronchial carcinoids has not yet been confirmed in prospective studies.",
"     </li>",
"     <li>",
"      A few objective responses have also been reported in case reports and small series of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , and capecitabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       liposomal doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/47,52-54\">",
"       47,52-54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that patients with advanced bronchial carcinoid may respond to cytotoxic chemotherapy, but the data are insufficient to permit a recommendation as to which specific regimen should be chosen. In our view, participation in clinical trials testing new strategies is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201262\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited efficacy of chemotherapy has prompted investigation of novel therapeutic approaches for patients with advanced carcinoids. These include mTOR inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ), inhibitors of angiogenesis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ), and small molecule tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ). Sunitinib and everolimus have been shown to improve outcomes in patients with advanced pancreatic neuroendocrine tumors, but the long-term benefits of these drugs is less certain for metastatic carcinoid tumors, either bronchial or nonbronchial in origin.",
"   </p>",
"   <p>",
"    A randomized phase III trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    LAR with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    in 429 patients with advanced carcinoid tumors, a history of carcinoid syndrome, and radiologic disease progression in the preceding 12 months demonstrated a clinically meaningful prolongation of progression-free survival (PFS) with combined therapy (median 16.4 versus 11.3 months), but the benefit was only of borderline statistical significance, and treatment-related toxicity was not trivial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/55\">",
"     55",
"    </a>",
"    ]. In a subgroup analysis of the 44 patients with bronchial carcinoids (33 randomized to everolimus plus octreotide and 11 to placebo plus octreotide), median progression free survival was longer in the group receiving everolimus (13.6 versus 5.6 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/56\">",
"     56",
"    </a>",
"    ]. Nearly one-half of the patients treated with everolimus had grade 3 or 4 adverse events (mainly diarrhea, stomatitis and thrombocytopenia). A follow-up trial is planned (the LUNA trial) that will randomly assign patients with bronchial or thymic carcinoid tumors to a long-acting form of the somatostatin receptor analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    , everolimus 10 mg daily, or the combination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4153/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecularly targeted treatments for advanced NET are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949026#H190949026\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Molecularly targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143201269\">",
"    <span class=\"h2\">",
"     Peptide receptor radioligand therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option for treatment of advanced disease, where available, is peptide receptor radioligand therapy (eg, radiolabeled somatostatin analogs such as 177Lu-octreotate, therapeutic I-131 MIBG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949111#H190949111\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Systemic radionuclide therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143202989\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoid tumors are malignant neoplasms that are characterized by neuroendocrine differentiation and indolent clinical behavior. Typical bronchial carcinoids seldom metastasize and have an excellent prognosis even when regional lymph nodes are involved; atypical carcinoids have a higher likelihood of metastases and a worse prognosis, particularly if mediastinal nodes are involved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with either a typical or atypical bronchial carcinoid whose medical condition and pulmonary reserve will tolerate it, we recommend surgical resection and mediastinal lymph node sampling or dissection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The presence of mediastinal lymph node metastases does not preclude cure. (See",
"      <a class=\"local\" href=\"#H1143201171\">",
"       'Surgical resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, endobronchial resection is a suboptimal method of definitive treatment, and we suggest not pursuing this approach over definitive surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endobronchial laser resection is best reserved for palliative treatment of patients with central airway occlusion who are poor surgical candidates (eg, elderly, debilitated). (See",
"      <a class=\"local\" href=\"#H1143201199\">",
"       'Endobronchial management'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Although some disagree, we suggest not administering postoperative adjuvant therapy for a completely resected bronchial carcinoid of any stage or histology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Radiation therapy is a reasonable option for atypical carcinoids if gross residual disease remains after surgery, although whether this improves outcomes is unproven. (See",
"      <a class=\"local\" href=\"#H1143201185\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite their low malignant potential, long-term follow-up of patients with bronchial carcinoids is warranted. Although the optimal posttreatment surveillance strategy is not defined, we suggest an annual history and physical examination as well as chest CT for typical carcinoids and every six month history and physical examination and chest CT for atypical carcinoids for two years, then yearly thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We reserve postoperative somatostatin receptor scintigraphy for patients who have a clinical suspicion for metastatic disease. (See",
"      <a class=\"local\" href=\"#H1143201220\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with surgically unresectable but nonmetastatic disease, options for local control of tumor growth include radiation therapy with or without concurrent chemotherapy and palliative endobronchial resection of obstructing tumor. (See",
"      <a class=\"local\" href=\"#H1143201213\">",
"       'Locally advanced unresectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a limited, potentially resectable liver-isolated metastatic carcinoid, we recommend surgical resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the majority of cases will not be cured by surgery, given the slow-growing nature of the tumor, extended survival is sometimes possible. (See",
"      <a class=\"local\" href=\"#H1143201234\">",
"       'Liver-directed therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other treatment options for patients with unresectable hepatic-predominant metastatic disease include embolization, chemoembolization, RFA, and cryoablation. (See",
"      <a class=\"local\" href=\"#H1143201234\">",
"       'Liver-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more advanced metastatic disease, first-line therapy with a somatostatin analog is reasonable. In progressing cases, a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy regimen such as that used for small cell lung cancer, single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      are reasonable options. (See",
"      <a class=\"local\" href=\"#H1143201255\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1143201262\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/1\">",
"      Terzi A, Lonardoni A, Feil B, et al. Bronchoplastic procedures for central carcinoid tumors: clinical experience. Eur J Cardiothorac Surg 2004; 26:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/2\">",
"      El Jamal M, Nicholson AG, Goldstraw P. The feasibility of conservative resection for carcinoid tumours: is pneumonectomy ever necessary for uncomplicated cases? Eur J Cardiothorac Surg 2000; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/3\">",
"      Lucchi M, Melfi F, Ribechini A, et al. Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. J Thorac Cardiovasc Surg 2007; 134:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/4\">",
"      Todd TR, Cooper JD, Weissberg D, et al. Bronchial carcinoid tumors: twenty years' experience. J Thorac Cardiovasc Surg 1980; 79:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/5\">",
"      Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg 2006; 18:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/6\">",
"      Cerfolio RJ, Deschamps C, Allen MS, et al. Mainstem bronchial sleeve resection with pulmonary preservation. Ann Thorac Surg 1996; 61:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/7\">",
"      Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg 2000; 18:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/8\">",
"      Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/9\">",
"      Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/10\">",
"      Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/11\">",
"      Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/12\">",
"      Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/13\">",
"      Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg 2005; 53:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/14\">",
"      Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest 2001; 119:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/15\">",
"      Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 2004; 77:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/16\">",
"      Ducrocq X, Thomas P, Massard G, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 1998; 65:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/17\">",
"      Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/18\">",
"      Soga J, Yakuwa Y. Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/19\">",
"      Matilla Gonzalez J, Garcia-Yuste M, Moreno-Mata N, et al. Typical and atypical carcinoid tumors (NEC grades 1 and 2): Prognostic factiors in metastaes and local recurrence (abstract). Lung Cancer 2005; 49(2 suppl):S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/20\">",
"      Chughtai TS, Morin JE, Sheiner NM, et al. Bronchial carcinoid--twenty years' experience defines a selective surgical approach. Surgery 1997; 122:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/21\">",
"      Harpole DH Jr, Feldman JM, Buchanan S, et al. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992; 54:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/22\">",
"      Aubry MC, Thomas CF Jr, Jett JR, et al. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 2007; 131:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/23\">",
"      Fiala P, Petr&aacute;skov&aacute; K, Cernohorsk&yacute; S, et al. Bronchial carcinoid tumors: long-term outcome after surgery. Neoplasma 2003; 50:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/24\">",
"      Martini N, Zaman MB, Bains MS, et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg 1994; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/25\">",
"      Kaplan B, Stevens CW, Allen P, et al. Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys 2003; 55:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/26\">",
"      Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000; 31:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/27\">",
"      Gould PM, Bonner JA, Sawyer TE, et al. Bronchial carcinoid tumors: importance of prognostic factors that influence patterns of recurrence and overall survival. Radiology 1998; 208:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/28\">",
"      Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002; 123:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/29\">",
"      Garc&iacute;a-Yuste M, Matilla JM, Alvarez-Gago T, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg 2000; 70:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/30\">",
"      Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg 2007; 31:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/31\">",
"      Machuca TN, Cardoso PF, Camargo SM, et al. Surgical treatment of bronchial carcinoid tumors: a single-center experience. Lung Cancer 2010; 70:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/32\">",
"      Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park) 2006; 20:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/33\">",
"      Marty-An&eacute; CH, Costes V, Pujol JL, et al. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 1995; 59:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/34\">",
"      Cooper WA, Thourani VH, Gal AA, et al. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001; 119:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/35\">",
"      Carretta A, Ceresoli GL, Arrigoni G, et al. Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases. Lung Cancer 2000; 29:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/36\">",
"      Perkins P, Kemp BL, Putnam JB Jr, Cox JD. Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior. Am J Clin Oncol 1997; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/37\">",
"      Brokx HA, Risse EK, Paul MA, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg 2007; 133:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/38\">",
"      van Boxem TJ, Golding RP, Venmans BJ, et al. High-resolution CT in patients with intraluminal typical bronchial carcinoid tumors treated with bronchoscopic therapy. Chest 2000; 117:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/39\">",
"      Berendsen HH, Postmus PE, Edens ET, Sluiter HJ. Irresectable bronchial carcinoid with a 32-year natural history. A report of two cases treated with Neodymium-YAG-laser, initially misinterpreted as small cell lung cancer. Eur J Respir Dis 1986; 68:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/40\">",
"      D&iacute;az-Jim&eacute;nez JP, Canela-Cardona M, Maestre-Alcacer J. Nd:YAG laser photoresection of low-grade malignant tumors of the tracheobronchial tree. Chest 1990; 97:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/41\">",
"      Orino K, Kawai H, Ogawa J. Bronchoscopic treatment with argon plasma coagulation for recurrent typical carcinoids: report of a case. Anticancer Res 2004; 24:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/42\">",
"      Schreurs AJ, Westermann CJ, van den Bosch JM, et al. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1992; 104:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/43\">",
"      Bertoletti L, Elleuch R, Kaczmarek D, et al. Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor. Chest 2006; 130:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/44\">",
"      Chakravarthy A, Abrams RA. Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer 1995; 75:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/45\">",
"      Wirth LJ, Carter MR, J&auml;nne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/46\">",
"      Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/47\">",
"      De Dosso S, Bajetta E, Procopio G, et al. Pulmonary carcinoid tumours: indolent but not benign. Oncology 2007; 73:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/48\">",
"      Zuetenhorst JM, Hoefnageli CA, Boot H, et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/49\">",
"      Fan JT, Ortiz RG, Buettner H. Regression of choroidal metastases from a bronchial carcinoid tumor after chemotherapy with cisplatin and etoposide. Am J Ophthalmol 1994; 117:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/50\">",
"      Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/51\">",
"      Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/52\">",
"      Masi G, Fornaro L, Cupini S, et al. Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. Nat Rev Clin Oncol 2009; 6:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/53\">",
"      Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/54\">",
"      Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/55\">",
"      Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4153/abstract/56\">",
"      Fazio N, Granberg D, Grossman A, et al. Everolimus Plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumors: Analysis of the Phase III, Randomized, Placebo-Controlled RADIANT-2 Study. Chest 2012.",
"     </a>",
"    </li>",
"    <li>",
"     INformation on the LUNA trial available online at file://clinicaltrials.gov/ct2/show/NCT01563354?term=LUNA+trial&amp;rank=1 (Accessed on April 10, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85914 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4153=[""].join("\n");
var outline_f4_3_4153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1143202989\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1143202982\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201164\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201171\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7045450\">",
"      - Proximal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7045461\">",
"      - Peripheral tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7045468\">",
"      - Role of lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201178\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7045482\">",
"      Typical carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7045475\">",
"      Atypical carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201185\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201199\">",
"      Endobronchial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14397458\">",
"      - Endobronchial resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14397465\">",
"      - Endobronchial cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201213\">",
"      Locally advanced unresectable disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201220\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201227\">",
"      OVERVIEW OF MANAGEMENT OF METASTATIC CARCINOID AND THE CARCINOID SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201234\">",
"      Liver-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201241\">",
"      Somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201248\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201255\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201262\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1143201269\">",
"      Peptide receptor radioligand therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1143202989\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85914|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10237\" title=\"table 1\">",
"      Outcome typ atyp bronch car",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 2\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_3_4154="Methanol and ethylene glycol poisoning";
var content_f4_3_4154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methanol and ethylene glycol poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Marco L A Sivilotti, MD, MSc, FRCPC, FACEP, FACMT",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4154/contributors\">",
"     James F Winchester, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/3/4154/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/3/4154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methanol and ethylene glycol poisonings cause dozens of fatal intoxications in the United States (US) annually, and even relatively small ingestions of these alcohols can produce significant toxicity.",
"    <strong>",
"     Rapid recognition and early treatment, including alcohol dehydrogenase inhibition, are crucial.",
"    </strong>",
"    A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef66916 \" href=\"UTD.htm?8/3/8253\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Methanol and ethylene glycol are frequently found in high concentration in automotive antifreeze and de-icing solutions, windshield wiper fluid, solvents, cleaners, fuels, and other industrial products. Most serious poisonings occur following ingestion; inhalation and dermal exposures rarely cause toxicity.",
"   </p>",
"   <p>",
"    Patients may ingest toxic alcohols as an ethanol substitute, to inflict self-harm, or by accident, sometimes following transfer from the original container. Multiple victim methanol poisonings can occur with illicit distillation (\"moonshine\") or occult substitution for ethanol.",
"   </p>",
"   <p>",
"    To provide proper management, clinicians must understand the metabolic activation of these alcohols to their toxic acid metabolites, the limitations of available laboratory tests, and the indications for treatment with antidotes, with or without hemodialysis.",
"   </p>",
"   <p>",
"    The diagnosis and management of methanol and ethylene glycol intoxication will be reviewed here. Isopropyl alcohol intoxication and a general approach to the poisoned adult or child are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20423?source=see_link\">",
"     \"Isopropyl alcohol poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"parent alcohols\" methanol and ethylene glycol are relatively nontoxic, and cause mainly central nervous system (CNS) sedation. However, profound toxicity can ensue when these parent alcohols are oxidized (primarily by alcohol dehydrogenase and aldehyde dehydrogenase) (",
"    <a class=\"graphic graphic_figure graphicRef55124 \" href=\"UTD.htm?6/22/6509\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56013 \" href=\"UTD.htm?8/7/8318\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The methanol metabolite formate and the ethylene glycol metabolites glycolate, glyoxylate, and oxalate accumulate following large ingestions. Above plasma levels of approximately 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (approximately 6",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of methanol or 3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of ethylene glycol), these metabolites can cause specific end-organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formate causes retinal injury with optic disc hyperemia, edema, and eventually permanent blindness, as well as ischemic or hemorrhagic injury to the basal ganglia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/6\">",
"       6",
"      </a>",
"      ]. These changes are postulated to result from disruption of mitochondrial function.",
"     </li>",
"     <li>",
"      Ethylene glycol metabolites target the kidney and lead to reversible oliguric or anuric acute kidney injury (acute renal failure), which in turn slows elimination of ethylene glycol [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/7\">",
"       7",
"      </a>",
"      ]. The renal failure is primarily due to glycolate-induced damage to tubules, although tubule obstruction from precipitated oxalate crystals may contribute [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Hypocalcemia in ethylene glycol overdose results from calcium oxalate formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With ingestions of either parent alcohol, a profound anion gap metabolic acidosis develops, which directly correlates with the accumulation of toxic acid metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Acidemia increases the ability of the toxic metabolites to penetrate cells, further depressing CNS function and causing a rapid downward spiral of hypoxia and acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other simple alcohols, methanol and ethylene glycol are rapidly and completely absorbed after oral ingestion. Peak serum alcohol concentrations are reached within one to two hours. Two-step metabolism via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase leads to the production of toxic species. Methanol elimination follows zero-order kinetics in the absence of treatment, and has been estimated at 8.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    per hour following overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/11\">",
"     11",
"    </a>",
"    ]. Ethylene glycol elimination appears to follow first-order kinetics in the absence of treatment, with an estimated serum half-life of between three and nine hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/7,12\">",
"     7,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If hepatic oxidation is inhibited (\"blocked\") by an alcohol dehydrogenase antagonist, such as ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    , several changes occur (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Alcohol dehydrogenase inhibition'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For methanol, elimination shifts to the pulmonary and renal routes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/13,14\">",
"       13,14",
"      </a>",
"      ], becomes first-order, and slows dramatically (half-life of 48 to 54 hours).",
"     </li>",
"     <li>",
"      For ethylene glycol, elimination after ADH inhibition becomes almost entirely renal, with a half-life as short as 14 hours when kidney function is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/7,15\">",
"       7,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elimination of formate, the toxic metabolite of methanol, is partially dependent upon tetrahydrofolate, and is thought to accelerate following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/8\">",
"     8",
"    </a>",
"    ]. Pyridoxine and thiamine are involved in minor elimination pathways of glycolate, an ethylene glycol metabolite, but it is not known if pyridoxine and thiamine supplementation accelerates metabolism along these minor pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Cofactor therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should make every effort to identify the original source and nature of the exposure. This is ideally done by retrieving the original container and consulting product databases, as well as interviewing the patient, relatives, and prehospital workers. Methanol and ethylene glycol are frequently found in high concentration in automotive antifreeze and de-icing solutions, windshield wiper fluid, solvents, cleaners, fuels, and other industrial products. Most serious poisonings occur following ingestion. \"Antifreeze\" may contain a different alcohol than originally suspected (eg, propylene glycol rather than ethylene glycol). Such information dramatically changes the treatment strategy, underscoring the need to obtain accurate information.",
"   </p>",
"   <p>",
"    In the absence of treatment, an ingestion of approximately 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of either methanol or ethylene glycol (ie, parent alcohols) is considered lethal, and serious toxicity has been reported following ingestions of as little as one teaspoon of methanol. Inhalation and dermal exposures rarely cause toxicity. Product labels rarely provide the concentrations of toxic alcohols. As an approximate guide, a 50 percent",
"    <span class=\"nowrap\">",
"     vol/vol",
"    </span>",
"    solution contains 0.4",
"    <span class=\"nowrap\">",
"     g/mL",
"    </span>",
"    of methanol or 0.6",
"    <span class=\"nowrap\">",
"     g/mL",
"    </span>",
"    of ethylene glycol.",
"   </p>",
"   <p>",
"    It is important to clarify when the ingestion occurred and whether ethanol was also ingested. As mentioned above, ethanol competitively inhibits alcohol dehydrogenase, thereby diminishing formation of toxic metabolites of the parent compound.",
"   </p>",
"   <p>",
"    The intent of the exposure (whether accidental, suicidal, or homicidal) may only become apparent with closer investigation (eg, interview of friends and family). The identification of other potential victims may depend upon understanding the circumstances of the exposure (eg, occult substitution for ethanol). (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complaints of visual blurring, central scotomata, and blindness suggest methanol poisoning. Flank pain, hematuria, and oliguria suggest ethylene glycol poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief initial screening examination, including vital signs, mental status, and pupils, should be performed to identify immediate measures required to stabilize the patient. A discussion of the fundamental evaluation of the poisoned patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with large ingestions of methanol or ethylene glycol may present with mild CNS effects, such as inebriation and sedation, similar to ethanol intoxication. Ethanol coingestion may exacerbate such symptoms. Coma, seizures, hyperpnea (Kussmaul-Kien respirations), and hypotension all suggest a substantial portion of the parent alcohol has been metabolized to its toxic byproducts.",
"   </p>",
"   <p>",
"    An afferent pupillary defect is an ominous sign of advanced methanol poisoning. Eye examination in methanol poisoning may also reveal mydriasis, a retinal sheen due to retinal edema, and hyperemia of the optic disk.",
"   </p>",
"   <p>",
"    It is important to emphasize that the onset of methanol or ethylene glycol toxicity is delayed when ethanol is coingested. The possibility of concomitant ethanol and toxic alcohol ingestion must always be considered, particularly in alcoholics, who may ingest alcohol in any form.",
"   </p>",
"   <p>",
"    Ethylene glycol metabolism can lead to cranial nerve palsies and tetany (thought to result from oxalate-induced hypocalcemia). Oliguria and hematuria may occur. Cerebral herniation and multisystem organ failure are common preterminal events in patients with profound poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pending definitive parent alcohol concentrations, the clinician should form a differential diagnosis based upon the available clinical information.",
"   </p>",
"   <p>",
"    Few conditions other than methanol and ethylene glycol intoxication cause a profound high anion gap metabolic acidosis (serum bicarbonate less than 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (or 8",
"    <span class=\"nowrap\">",
"     mmol/L)),",
"    </span>",
"    and most of these conditions present in a characteristic fashion with a high serum lactate (eg, status epilepticus, profound shock, ischemic bowel) or diabetic ketoacidosis (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"UTD.htm?38/0/38924\">",
"     table 2",
"    </a>",
"    ). Although some patients with ethylene glycol poisoning present with elevated lactate levels, the rise in lactate is insufficient to account for the degree of acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lesser degree of metabolic acidosis in an alcoholic patient may also be caused by alcoholic ketoacidosis, sepsis, alcohol withdrawal seizures, diabetic ketoacidosis, or salicylate intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=see_link\">",
"     \"Alcoholic and fasting ketoacidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevated plasma osmolal gap can be seen in patients with methanol or ethylene glycol intoxication, but also in alcoholic or diabetic ketoacidosis, isopropyl alcohol ingestion, large ethanol ingestions, and other serious illnesses (eg, sepsis, ischemic bowel, shock) (",
"    <a class=\"graphic graphic_table graphicRef81217 \" href=\"UTD.htm?18/9/18587\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Plasma osmolal gap'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20423?source=see_link\">",
"     \"Isopropyl alcohol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traces of methanol may be detectable in alcoholic patients drinking fermented beverages such as wine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Basic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of any poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals; it is important to note that ethylene glycol can prolong the QTc interval via its effects on serum calcium",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Additional tests with toxic alcohol exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients suspected of toxic alcohol exposure should undergo additional laboratory evaluation including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basic electrolytes with anion gap determination",
"     </li>",
"     <li>",
"      Serum calcium",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Arterial or venous blood gas analysis",
"     </li>",
"     <li>",
"      Serum ethanol concentration",
"     </li>",
"     <li>",
"      Serum osmolality",
"     </li>",
"     <li>",
"      Serum methanol, ethylene glycol, and isopropyl alcohol concentrations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pitfalls in laboratory testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Testing for methanol and ethylene glycol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of serum methanol and ethylene glycol concentrations is usually performed by gas chromatography, but such testing is not widely available and frequently must be performed at a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. Such \"send out\" laboratory testing rarely, if ever, gives results in time to assist clinical decision-making.",
"   </p>",
"   <p>",
"    Some laboratories report a \"solvent screen\" that does not include ethylene glycol and may falsely reassure clinicians. Thus, if a \"solvent screen\" is performed, the clinician should clarify exactly which solvents are detected by the test.",
"   </p>",
"   <p>",
"    Enzymatic methods of ethylene glycol detection are still used in many laboratories, but they can lead to false-positive results (eg, from severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity, or interference from propylene glycol, 2, 3-butanediol, or glycolate) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend relying on these tests when evaluating patients with potential ethylene glycol toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ethylene glycol poisoning can have elevations in their serum lactate concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/19\">",
"     19",
"    </a>",
"    ]. In some cases, such elevations (usually minor) can be caused by actual increases in lactate. However, in other cases such elevations may be substantial and are likely to be caused by the misinterpretations of some laboratory instruments that cannot differentiate between lactate and glycolate, a metabolite of ethylene glycol that is structurally similar to lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/17,20-23\">",
"     17,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A markedly elevated lactate concentration may be the first test result reported in a severely acidotic patient, now that lactate testing has become readily available, and traditionally suggests alternative diagnoses (eg, tissue hypoxia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    poisoning). However, it is important",
"    <strong>",
"     NOT",
"    </strong>",
"    to exclude ethylene glycol as a possible cause of acidosis associated with an elevated lactate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Urine testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the urine for oxalate crystals and fluorescence is frequently performed in patients with possible ethylene glycol poisoning, but care should be taken not to over-interpret positive or negative results. The formation of oxalate crystals in the urine is a late and",
"    <strong>",
"     NONSPECIFIC",
"    </strong>",
"    finding following ethylene glycol ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Two types of calcium oxalate crystals may be seen: needle-shaped monohydrate crystals, which may be misread as hippurate crystals, and envelope-shaped dihydrate crystals (",
"    <a class=\"graphic graphic_picture graphicRef67694 graphicRef65169 \" href=\"UTD.htm?16/28/16836\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Urine fluorescence is a poor diagnostic test that uses ultraviolet light to detect the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    added to most antifreeze solutions. Urine fluorescence lacks sensitivity, as not all ethylene glycol preparations contain fluorescein, and fluorescein (when present) appears only transiently in the urine following ingestion. Urine fluorescence also lacks specificity because normal urine can appear to fluoresce and other substances unrelated to ethylene glycol poisoning can cause fluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/16,24,25\">",
"     16,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Plasma osmolal gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoscopic osmometry is widely used to measure plasma osmolality and to estimate the so-called osmolal gap. While the test must be interpreted cautiously, as described below, an unexplained, large osmolal gap is presumptive evidence of a recent methanol, ethylene glycol, or isopropyl alcohol exposure in the appropriate clinical setting, provided a significant ethanol ingestion has been excluded.",
"   </p>",
"   <p>",
"    The osmolal gap is the difference between the measured osmolality and the calculated plasma osmolality:",
"   </p>",
"   <p>",
"    &nbsp;Calculated Posm &nbsp;= &nbsp;(2 &nbsp;x &nbsp;plasma [Na]) &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [glucose]/18",
"    </span>",
"    &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [BUN]/2.8",
"    </span>",
"   </p>",
"   <p>",
"    or, using standard units",
"    <span class=\"nowrap\">",
"     (mmol/L):",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Calculated Posm &nbsp;= &nbsp;(2 &nbsp;x &nbsp;plasma [Na]) &nbsp;+ &nbsp;[glucose] &nbsp;+ &nbsp;[urea]",
"   </p>",
"   <p>",
"    The serum sodium is multiplied by two to account for accompanying anions (chloride and bicarbonate) and the divisors 18 and 2.8 in the first formula convert units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    into",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"   </p>",
"   <p>",
"    Details of the plasma osmolal gap and its measurement are discussed separately, but its use in methanol and ethylene glycol intoxication will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .) Calculators to determine the osmolal gap are provided (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The plasma osmolal gap can provide important information in real time, costs little, and is widely available. Clinicians need to be able to interpret this test for early treatment decision-making, pending definitive poison identification by gas chromatography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,26-29\">",
"     14,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When interpreting the plasma osmolal gap in the setting of a toxic alcohol ingestion, clinicians should keep in mind several potential pitfalls:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The plasma osmolal gap",
"      <strong>",
"       cannot",
"      </strong>",
"      distinguish among ethanol, isopropyl alcohol, methanol, or ethylene glycol. Therefore, ethanol administration (if performed) mitigates the value of following the osmolal gap when assessing the response to treatment of toxic alcohols.",
"     </li>",
"     <li>",
"      The plasma osmolal gap estimates the molar quantity of uncharged molecules and therefore increases only in the presence of the",
"      <strong>",
"       parent",
"      </strong>",
"      alcohols. The toxic acid metabolites of methanol (formate) and ethylene glycol (glycolate, glyoxylate, and oxalate) exist primarily in a dissociated (ie, charged) form at physiologic pH; since these anions must be accompanied by a cation (mostly sodium), they do",
"      <strong>",
"       not",
"      </strong>",
"      contribute to the calculated osmolal gap. As a result, the plasma osmolal gap is",
"      <strong>",
"       insensitive in",
"      </strong>",
"      <strong>",
"       late presentations",
"      </strong>",
"      , since most of the parent alcohol has already been metabolized.",
"     </li>",
"     <li>",
"      The plasma osmolal gap is not sufficiently sensitive to exclude a",
"      <strong>",
"       small ingestion",
"      </strong>",
"      even shortly after ingestion. The variability of the test means that despite a substantial ingestion (eg, serum concentrations up to 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (8.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      of ethylene glycol), the plasma osmolal gap can fall within the upper limits of the normal range (generally less than 10",
"      <span class=\"nowrap\">",
"       mOsm/L",
"      </span>",
"      is considered normal). The plasma osmolal gap has been less than 10 in a small number of serious exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large quantities of ethanol (greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (or 22",
"      <span class=\"nowrap\">",
"       mmol/L))",
"      </span>",
"      can raise the osmolal gap more than would be expected based on its molecular weight. This occurs because serum does not behave as an ideal fluid and because mathematical approximations are used in calculating the osmolal gap. We recommend that the measured serum ethanol level be increased by 20 to 25 percent when performing plasma osmolal gap calculations to enable a more accurate interpretation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should also note that patients who are critically ill may have elevated plasma osmolal gaps, due to so-called idiogenic osmoles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link&amp;anchor=H9#H9\">",
"     \"Serum osmolal gap\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, the practice of categorically ruling out methanol or ethylene glycol exposure on the basis of a plasma osmolal gap less than 10 units is unjustified, as is assuming that a small elevation in the plasma osmolal gap in a patient with a low pretest probability is due to a toxic alcohol.",
"   </p>",
"   <p>",
"    On the other hand, few substances cause a very high (greater than 25) plasma osmolal gap, and most severely poisoned methanol and ethylene glycol patients manifest plasma osmolal gaps of this magnitude shortly after ingestion. An unexplained, large osmolal gap is presumptive evidence of a recent methanol, ethylene glycol, or isopropyl alcohol exposure in the appropriate clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,28\">",
"     14,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview of emergent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid decision-making is critical in the management of the patient poisoned with methanol or ethylene glycol. The clinician must often make treatment decisions without definitive serum drug levels, based only upon clinical suspicion and readily available laboratory data. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef66916 \" href=\"UTD.htm?8/3/8253\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The management of methanol and ethylene glycol poisoning involves the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Securing the patient's airway, breathing, and circulation, and providing appropriate supportive care",
"     </li>",
"     <li>",
"      Administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to correct systemic acidosis, which limits the penetration of toxic acids (eg, formic acid) into end-organ tissues such as the retina by converting them to the anion (eg, formate), which cannot diffuse across cell membrane",
"     </li>",
"     <li>",
"      Inhibiting the enzyme alcohol dehydrogenase, with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      (preferred) or ethanol (if fomepizole is unavailable)",
"     </li>",
"     <li>",
"      Performing hemodialysis for elevated toxic alcohol levels, severe acid-base derangements, or evidence of end-organ toxicity",
"     </li>",
"     <li>",
"      Treating with cofactors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , thiamine, and pyridoxine) to optimize nontoxic metabolic pathways for the elimination of the parent alcohol or its metabolites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also recommend immediate consultation with a medical toxicologist or poison control center, if methanol or ethylene glycol intoxication is suspected. (See",
"    <a class=\"local\" href=\"#H10832275\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Airway, breathing, circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must first assess and secure the patient's airway, breathing, and circulation. Advanced cardiac life support measures are provided as required. A discussion of fundamental management of the poisoned patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If endotracheal intubation is required, the patient should be hyperventilated, if a significant metabolic acidosis exists or is suspected. Arterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venous blood gas analysis should be performed frequently to evaluate pH and ensure adequate ventilation and oxygenation. Large minute ventilations may be required to prevent profound acidemia (pH &lt;7.1) in patients with severe intoxication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little, if any, role for gastrointestinal (GI) decontamination in methanol or ethylene glycol poisoning, as these simple alcohols are rapidly absorbed. The rare patient known to have ingested a large amount of methanol or ethylene glycol may benefit from gastric aspiration via flexible nasogastric tubing if performed within 60 minutes of the ingestion.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC), gastric lavage, and syrup of ipecac have no role in the management of toxic alcohol exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment with sodium bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methanol is metabolized to formate, and ethylene glycol to glycolate, glyoxylate, and oxalate. Acidemia leads to protonation of these species to uncharged molecules (eg, formic acid), making them more likely to penetrate end-organ tissues (such as the retina) and more likely to be reabsorbed across the renal epithelium from the urine. Thus, patients with methanol or ethylene glycol poisoning fare worse when systemic acidemia is present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    leads to deprotonation of these acid species, making them less likely to penetrate end-organ tissues and more likely to be excreted in the urine.",
"   </p>",
"   <p>",
"    Despite this clear rationale, no clear evidence exists to determine how bicarbonate should be given. We suggest initial treatment with 1 to 2",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    via IV bolus for any patient with a pH below 7.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. A maintenance infusion is then prepared by mixing approximately 133 meq of sodium bicarbonate in 1 liter of D5W. Infusion rates may range from 150 to 250",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    in adults, or one to two times the maintenance fluid rate in children. The appropriate rate depends upon the initial pH, and such parameters as fluid status and serum sodium concentration. The goal of treatment is maintenance of an arterial or venous pH above 7.35, at which point the infusion is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Alcohol dehydrogenase inhibition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Approach and initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of alcohol dehydrogenase (ADH) blocks bioactivation of the parent alcohol to its toxic acid metabolites. Early treatment is crucial since ADH inhibition does not prevent toxicity if complete metabolism to acid species has already occurred.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     Fomepizole",
"    </a>",
"    or ethanol can be used to inhibit ADH (",
"    <a class=\"graphic graphic_table graphicRef70292 \" href=\"UTD.htm?11/60/12235\">",
"     table 4",
"    </a>",
"    ). We recommend treatment with fomepizole. The American Academy of Clinical Toxicology (AACT) practice guidelines provide some guidance for the initiation of ADH inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Fomepizole'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The AACT's minimum treatment threshold of 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    of either methanol [SI equivalent 6.2",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or ethylene glycol [SI equivalent 3.2",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    is not evidence-based and is necessarily conservative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Parent alcohol concentrations must be interpreted in clinical context. As an example, a patient with a methanol level of 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (or 7.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and a normal acid base-status may only require one or two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    and observation, whereas a patient with the same level, but a significant acidosis and vision deficits may require fomepizole, alkalinization, and hemodialysis. Making such determinations can be difficult and we recommend consultation with a regional poison control center or medical toxicologist in such cases. (See",
"    <a class=\"local\" href=\"#H10832275\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of confirmatory drug levels, clinicians must rely upon their clinical judgment and readily available laboratory tests when deciding whether to initiate therapy with an ADH inhibitor. Clinicians should be wary of initiating such therapy solely on the basis of an anion gap or small osmolal gap without at least circumstantial evidence of toxic alcohol ingestion, especially when ethanol therapy is contemplated. In addition, the clinician should not ascribe metabolic acidosis to a toxic alcohol ingestion if coingested ethanol is present: substantial oxidation of the toxic alcohol is highly unlikely in the presence of ethanol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fomepizole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     Fomepizole",
"    </a>",
"    has been used successfully for years to treat both methanol and ethylene glycol poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/38-40\">",
"     38-40",
"    </a>",
"    ] and is a superior antidote to ethanol [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/12,41-44\">",
"     12,41-44",
"    </a>",
"    ]. Fomepizole is easy to dose, easy to administer, and side effects are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/45\">",
"     45",
"    </a>",
"    ]. Its main disadvantage is its high cost. However, the cost compares favorably with the total cost of managing patients treated with ethanol, including ethanol titration and possibly hemodialysis and intensive care unit admission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/7,43,46\">",
"     7,43,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     Fomepizole",
"    </a>",
"    is loaded at 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, followed by 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, with adjustments for hemodialysis or after more than two days of therapy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once begun, ADH inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    should be continued until the diagnosis of toxic alcohol ingestion has been ruled out, or until blood pH is normal and serum alcohol concentration is less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [SI units: methanol 6.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and ethylene glycol 3.2",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    in the presence of retinal or renal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ethanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, ethanol has been used as a competitive inhibitor of ADH, as ADH has greater affinity for ethanol than for methanol or ethylene glycol. Although effective, intravenous ethanol treatment creates several problems [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethanol is difficult to dose, and appropriate levels are difficult to maintain; as a result, frequent testing and infusion adjustments are often required.",
"     </li>",
"     <li>",
"      Ethanol requires compounding by the hospital pharmacy, irritates veins when infused, and can complicate fluid balance in oliguric patients.",
"     </li>",
"     <li>",
"      Most limiting are the sedative and behavioral effects of ethanol, which can cause obtundation, thereby increasing the risk of aspiration, and other complications [",
"      <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethanol therapy may pose significant risks in certain patients (eg, upper gastrointestinal bleeding, first trimester pregnancy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     Fomepizole",
"    </a>",
"    is the preferred therapy. In the rare circumstance in which ethanol therapy must be used, the appropriate target for therapy is a serum ethanol concentration of at least one-third of the serum methanol or ethylene glycol concentration expressed as",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    since inhibition is competitive. Although many sources cite an absolute ethanol level of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (or 22",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    we prefer the empiric approach to therapeutic goals and dosing described here because it avoids confusion and the potential dosing errors that can occur when making precise calculations for an antidote that is used infrequently and often in stressful circumstances.",
"   </p>",
"   <p>",
"    An intravenous loading dose of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of a 10 percent ethanol",
"    <span class=\"nowrap\">",
"     (volume/volume)",
"    </span>",
"    solution in D5W (ie, 800",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ethanol) will raise serum ethanol concentrations by about 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The loading dose should be given over 60 minutes to avoid excessive side effects (eg, hypotension, respiratory depression, somnolence). A maintenance infusion of the 10 percent ethanol solution, starting at 1",
"    <span class=\"nowrap\">",
"     mL/",
"    </span>",
"    kg per hour should be titrated according to serial ethanol concentrations (measured every one to two hours initially and following any change in dose or infusion rate), and increased by about 50 percent during hemodialysis. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hemodialysis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Once begun, ADH inhibition with ethanol should be continued until the diagnosis of toxic alcohol ingestion has been ruled out, or until blood pH is normal and serum alcohol concentration is less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [SI units: methanol 6.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and ethylene glycol 3.2",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    in the presence of retinal or renal injury.",
"   </p>",
"   <p>",
"    Due to the risks associated with ethanol therapy, patients should be treated in a critical care setting where their mental status and respiratory function can be closely monitored. Whenever possible, ethanol should be administered by central venous catheter using an infusion pump to limit venous irritation.",
"   </p>",
"   <p>",
"    Should both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    and pharmaceutical-grade intravenous ethanol be unavailable, ethanol can also be administered orally, both to load and to maintain serum ethanol concentrations as described above. Distilled spirits (40 to 50 percent",
"    <span class=\"nowrap\">",
"     vol/vol)",
"    </span>",
"    intended for human consumption can be diluted to a 20 percent solution, and administered",
"    <em>",
"     per os",
"    </em>",
"    or via nasogastric tube at double the volumes recommended above (ie, 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of a 20 percent solution to raise serum concentrations by 100",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for the initial maintenance dose). Gastritis and vomiting are occasionally encountered when using the enteral route for antidotal ethanol therapy, in addition to the other adverse effects of ethanol.",
"   </p>",
"   <p>",
"    There is no benefit to adding ethanol therapy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    therapy in methanol and ethylene glycol-poisoned patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis is the best method to rapidly remove both toxic acid metabolites and parent alcohols, and it plays a fundamental role in treating severely poisoned patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,28\">",
"     14,28",
"    </a>",
"    ]. Emergency clinicians should initiate consultation with a nephrologist immediately if they suspect a toxic alcohol ingestion and the patient has evidence of end-organ dysfunction or acidemia, especially if transfer to a hemodialysis center may be necessary.",
"   </p>",
"   <p>",
"    In such cases, consultation should not be delayed until confirmatory methanol or ethylene glycol levels are obtained. An arterial or venous blood gas serves as an essential triage tool in this setting. This is particularly true when caring simultaneously for multiple poisoned patients with limited hemodialysis capability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend immediate treatment with hemodialysis in the setting of a",
"    <strong>",
"     known",
"    </strong>",
"    methanol or ethylene glycol ingestion if either of the following conditions is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High anion gap metabolic acidosis, regardless of drug level",
"     </li>",
"     <li>",
"      Evidence of end-organ damage (eg, visual changes, renal failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we suggest treatment with hemodialysis in any patient with a",
"    <strong>",
"     suspected",
"    </strong>",
"    toxic alcohol ingestion who has a severe, otherwise unexplained anion gap metabolic acidosis and significant plasma osmolal gap. It is difficult to provide precise thresholds for determining when hemodialysis should be performed when the ingestion is uncertain. If a toxic ingestion is strongly suspected, a threshold pH of 7.30 is reasonable; if suspicion is weaker, a pH of 7.10 may be more appropriate. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Interpreting available clinical information (eg, nature and intent of exposure, pH, osmolarity) to decide whether to initiate hemodialysis can be challenging when confirmatory methanol and ethylene glycol concentrations are unavailable. We encourage clinicians facing this difficulty to consult with a poison control center, medical toxicologist, or other physician experienced in the management of suspected toxic alcohol exposure.",
"   </p>",
"   <p>",
"    For nonacidemic patients, hemodialysis can be used to clear the parent alcohol and abbreviate the course of antidotal therapy. There is less urgency to treat with hemodialysis if ADH inhibition is adequate. Hemodialysis is often unnecessary in patients with unmetabolized ethylene glycol provided that [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       Fomepizole",
"      </a>",
"      is given (prolonged ethanol therapy is impractical)",
"     </li>",
"     <li>",
"      The serum pH is normal or near normal (ie, little glycolate is present)",
"     </li>",
"     <li>",
"      The serum creatinine remains normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with ethylene glycol concentrations greater than 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [48",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    have been successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    alone when therapy was initiated before the appearance of acidosis. Treatment with hemodialysis is still recommended for large methanol ingestions because serum methanol elimination becomes extremely slow when ADH is inhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/28,49,50\">",
"     28,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hemodialysis prescription should include a large surface area dialyzer (&gt;1.5 m&sup2;), a blood flow rate in excess of 300",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and a bicarbonate bath. Hemodialysis should continue until the serum pH is normal and parent alcohol concentrations are less than approximately 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 5",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    The duration of hemodialysis in hours can be estimated using the formula -V ln",
"    <span class=\"nowrap\">",
"     (5/A)/0.06",
"    </span>",
"    k, where V is total body water in liters, A is the initial alcohol concentration in",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    and k is 80 percent of the dialyzer urea clearance in",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at the observed blood flow rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Serum alcohol concentrations should be verified near the end of hemodialysis and again two hours post-hemodialysis to ascertain the adequacy of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9642?source=see_link\">",
"     \"Acute hemodialysis prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than one round of hemodialysis may be necessary in massive overdoses and for ethylene glycol-poisoned patients with renal failure. Renal function often recovers over a period of days to months in survivors of ethylene glycol poisoning.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     Fomepizole",
"    </a>",
"    is dialyzable, and the frequency of its dosing should be increased to every four hours during hemodialysis. An additional dose should be given at the beginning of hemodialysis if six or more hours have elapsed since the prior dose.",
"   </p>",
"   <p>",
"    If ethanol is used for alcohol dehydrogenase (ADH) inhibition, adjustments in the dose must be made during hemodialysis. A fall in ethanol levels can be avoided or ameliorated by increasing the rate of ethanol infusion and possibly by adding ethanol directly to the dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In one such case, a dialysate ethanol concentration of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was prepared by administering a 95 percent ethanol solution into the dialysate inlet tubing at a rate of 40",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    via an infusion pump. The dialysate flow rate was maintained at 500",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and the dialyzer blood flow averaged 280",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    An average plasma ethanol level of 90",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was obtained during the six-hour hemodialysis session.",
"   </p>",
"   <p>",
"    Peritoneal dialysis and other forms of continuous renal replacement therapy are inefficient at clearing toxic alcohols and their metabolites and are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cofactor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All methanol patients treated with ADH inhibition should also receive cofactor therapy: either folinic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) 50 mg IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    50 mg IV every six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/28,56,57\">",
"     28,56,57",
"    </a>",
"    ]. It is not known whether supplemental thiamine (100 mg IV) or pyridoxine (50 mg IV) benefits patients poisoned with ethylene glycol, but we routinely administer both, particularly if the patient's nutritional status is suspect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Preterminal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely poisoned patients who present in coma may not survive despite maximum intensive therapy. Consideration should be given to organ harvesting prior to withdrawal of support for such patients, especially after severe methanol poisoning. Formate is a highly specific neurotoxin, and case series support the viability of other organs harvested from such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Younger children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common clinical presentation involves the child who may have swallowed one or two mouthfuls of a concentrated methanol or ethylene glycol solution. These children should not be managed at home [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most victims of unintentional exposure present for evaluation shortly after ingestion and do not manifest significant metabolic acidosis or any evidence of end-organ dysfunction. The ideal approach is to measure the serum concentration of the specific alcohol in order to quantify the absorbed dose and predict the clinical course. Unfortunately, such concentrations are rarely available within a few hours of the ingestion, creating a diagnostic and therapeutic dilemma.",
"   </p>",
"   <p>",
"    One approach to this problem (described below) can be used if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ingestion was unintentional and of small volume",
"     </li>",
"     <li>",
"      The product is accurately identified",
"     </li>",
"     <li>",
"      The patient is asymptomatic",
"     </li>",
"     <li>",
"      The patient has a normal pH and normal anion gap",
"     </li>",
"     <li>",
"      There is no coingestion or treatment with ethanol or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If all conditions are met, the clinician can observe the patient and monitor venous blood gases and electrolytes every one to two hours to exclude the development of a metabolic acidosis or an increasing anion gap. If acidosis does not develop within eight hours of the ingestion, a toxic alcohol poisoning can be excluded. Alcohol dehydrogenase (ADH) inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    or ethanol should NOT be initiated during this observation period, as such treatment will prevent the development of acidosis even in patients with massive ingestions. Treatment with fomepizole or ethanol invalidates the above protocol.",
"   </p>",
"   <p>",
"    Parents should be counseled about safe storage of household products and pharmaceuticals prior to discharge.",
"   </p>",
"   <p>",
"    Occasionally, infants with inherited metabolic disorders such as methylmalonic acidemia present with features that resemble ethylene glycol poisoning, and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/3/4154/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The clinician should obtain organic acid testing in all infants presenting with unexplained metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups of adolescents trying to become inebriated may consume toxic alcohols knowingly or accidentally in contaminated beverages. When treating an adolescent for a possible toxic alcohol ingestion, clinicians should always consider the possibility of other as-yet unidentified victims.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10832275\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methanol and ethylene glycol poisonings cause dozens of fatal intoxications in the United States annually.",
"    <strong>",
"     Rapid recognition and early treatment are crucial.",
"    </strong>",
"    A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef66916 \" href=\"UTD.htm?8/3/8253\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"parent alcohols\" methanol and ethylene glycol are themselves relatively nontoxic, causing mainly central nervous system sedation. The methanol metabolite formate can cause retinal and basal ganglia injury, and the ethylene glycol metabolites can cause renal failure following large ingestions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methanol and ethylene glycol are rapidly and completely absorbed after oral ingestion. Peak serum alcohol concentrations are reached within one to two hours.",
"     </li>",
"     <li>",
"      The clinician should make every effort to identify the source and nature of the exposure. This is ideally done by retrieving the original container and consulting product databases. It is important to clarify when the ingestion occurred, whether ethanol was also ingested, and the intent of the exposure (whether accidental, suicidal, or homicidal). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ingestion of approximately 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of either methanol or ethylene glycol is considered lethal, and serious toxicity has been reported following ingestions of as little as 8 g of methanol.",
"     </li>",
"     <li>",
"      Complaints of visual blurring, central scotomata, and blindness suggest methanol poisoning. Flank pain and hematuria suggest ethylene glycol poisoning. Coma, seizures, hyperpnea, and hypotension all suggest a substantial portion of the parent alcohols has been metabolized to toxic acids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Few conditions other than methanol and ethylene glycol intoxication present with a profound metabolic acidosis (serum bicarbonate less than 8",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      and most of these conditions present in a characteristic fashion (eg, status epilepticus, profound shock, ischemic bowel) (",
"      <a class=\"graphic graphic_table graphicRef77464 \" href=\"UTD.htm?38/0/38924\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct testing of toxic alcohols is the preferred diagnostic test when available. If a \"solvent screen\" is performed, the clinician should clarify exactly which solvents are detected by the test. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Pitfalls in laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Few substances cause a very high (greater than 25 mOsm) osmolal gap, and most severely poisoned methanol and ethylene glycol patients manifest osmolal gaps of this magnitude shortly after ingestion. An unexplained, large osmolal gap is presumptive evidence of a recent methanol, ethylene glycol, or isopropyl alcohol exposure in the appropriate clinical setting. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Plasma osmolal gap'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First assess and secure the patient's airway, breathing, and circulation. If mechanical ventilation is required, large minute ventilations may be needed to prevent profound acidemia (pH &lt;7.1) in patients with severe intoxication. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Airway, breathing, circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with methanol or ethylene glycol poisoning fare worse when systemic acidemia is present. For patients with a serum pH below 7.3, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Begin treatment with 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      of sodium bicarbonate via IV bolus infusion. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment with sodium bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that alcohol dehydrogenase (ADH) inhibition therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      be initiated in any patient in whom the clinician has strong suspicion of poisoning with either methanol or ethylene glycol coupled with an elevated plasma osmolal gap, or acidemia, or a measured methanol or ethylene glycol concentration over 20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      methanol [SI equivalent: methanol 6.2",
"      <span class=\"nowrap\">",
"       mmol/L;",
"      </span>",
"      ethylene glycol 3.2",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Fomepizole is loaded at 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously, followed by 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours, with adjustments for hemodialysis or after more than two days of therapy. If fomepizole is unavailable, we recommend treatment with ethanol in these same circumstances (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We provide cofactor therapy to all patients receiving ADH inhibition. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Alcohol dehydrogenase inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Cofactor therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend immediate hemodialysis be performed in the setting of a known methanol or ethylene glycol ingestion when the following conditions are present (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Metabolic acidosis, regardless of drug level",
"     </li>",
"     <li>",
"      Elevated serum levels of methanol or ethylene glycol (more than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [SI equivalent: methanol 15.6",
"      <span class=\"nowrap\">",
"       mmol/L;",
"      </span>",
"      ethylene glycol 8.1",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      unless arterial pH is above 7.3",
"     </li>",
"     <li>",
"      Evidence of end-organ damage (eg, visual changes, renal failure)",
"      <br/>",
"      <br/>",
"      We recommend treatment with hemodialysis if the clinician suspects a toxic alcohol ingestion in a patient with a severe, unexplained anion gap metabolic acidosis and significant osmolal gap (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We generally refrain from using hemodialysis to treat patients with elevated ethylene glycol concentrations, provided their serum pH is near normal, their renal function is normal, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      is given. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consultation with a medical toxicologist at a regional poison center is strongly recommended for all suspected exposures and for cases in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"       fomepizole",
"      </a>",
"      , ethanol, or hemodialysis therapy may be used. Consultation with nephrology and emergent hemodialysis should be immediately obtained for severely acidotic patients in whom the diagnosis appears likely, especially if accompanied by visual or renal impairment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Activated charcoal",
"      </a>",
"      (AC), gastric lavage, and syrup of ipecac have no role in the management of toxic alcohol exposures.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/1\">",
"      d'Alessandro A, Osterloh JD, Chuwers P, et al. Formate in serum and urine after controlled methanol exposure at the threshold limit value. Environ Health Perspect 1994; 102:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/2\">",
"      Kerns W 2nd, Tomaszewski C, McMartin K, et al. Formate kinetics in methanol poisoning. J Toxicol Clin Toxicol 2002; 40:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/3\">",
"      Liesivuori J, Savolainen H. Methanol and formic acid toxicity: biochemical mechanisms. Pharmacol Toxicol 1991; 69:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/4\">",
"      Moreau CL, Kerns W 2nd, Tomaszewski CA, et al. Glycolate kinetics and hemodialysis clearance in ethylene glycol poisoning. META Study Group. J Toxicol Clin Toxicol 1998; 36:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/5\">",
"      Fraser AD. Clinical toxicologic implications of ethylene glycol and glycolic acid poisoning. Ther Drug Monit 2002; 24:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/6\">",
"      Sivilotti ML, Burns MJ, Aaron CK, et al. Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole. J Toxicol Clin Toxicol 2001; 39:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/7\">",
"      Sivilotti ML, Burns MJ, McMartin KE, Brent J. Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group. Ann Emerg Med 2000; 36:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/8\">",
"      Jacobsen D, Hewlett TP, Webb R, et al. Ethylene glycol intoxication: evaluation of kinetics and crystalluria. Am J Med 1988; 84:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/9\">",
"      Bove KE. Ethylene glycol toxicity. Am J Clin Pathol 1966; 45:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/10\">",
"      Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol 1986; 1:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/11\">",
"      H&ouml;jer J. Severe metabolic acidosis in the alcoholic: differential diagnosis and management. Hum Exp Toxicol 1996; 15:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/12\">",
"      Jacobsen D, McMartin KE. Antidotes for methanol and ethylene glycol poisoning. J Toxicol Clin Toxicol 1997; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/13\">",
"      Malandain H, Cano Y. Interferences of glycerol, propylene glycol, and other diols in the enzymatic assay of ethylene glycol. Eur J Clin Chem Clin Biochem 1996; 34:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/14\">",
"      Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol 1999; 37:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/15\">",
"      Levine M, Curry SC, Ruha AM, et al. Ethylene glycol elimination kinetics and outcomes in patients managed without hemodialysis. Ann Emerg Med 2012; 59:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/16\">",
"      Casavant MJ, Shah MN, Battels R. Does fluorescent urine indicate antifreeze ingestion by children? Pediatrics 2001; 107:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/17\">",
"      Shirey T, Sivilotti M. Reaction of lactate electrodes to glycolate. Crit Care Med 1999; 27:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/18\">",
"      Church AS, Witting MD. Laboratory testing in ethanol, methanol, ethylene glycol, and isopropanol toxicities. J Emerg Med 1997; 15:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/19\">",
"      Gabow PA, Clay K, Sullivan JB, Lepoff R. Organic acids in ethylene glycol intoxication. Ann Intern Med 1986; 105:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/20\">",
"      Eder AF, Dowdy YG, Gardiner JA, et al. Serum lactate and lactate dehydrogenase in high concentrations interfere in enzymatic assay of ethylene glycol. Clin Chem 1996; 42:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/21\">",
"      Morgan TJ, Clark C, Clague A. Artifactual elevation of measured plasma L-lactate concentration in the presence of glycolate. Crit Care Med 1999; 27:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/22\">",
"      Porter WH, Crellin M, Rutter PW, Oeltgen P. Interference by glycolic acid in the Beckman synchron method for lactate: a useful clue for unsuspected ethylene glycol intoxication. Clin Chem 2000; 46:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/23\">",
"      Brindley PG, Butler MS, Cembrowski G, Brindley DN. Falsely elevated point-of-care lactate measurement after ingestion of ethylene glycol. CMAJ 2007; 176:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/24\">",
"      Wallace KL, Suchard JR, Curry SC, Reagan C. Diagnostic use of physicians' detection of urine fluorescence in a simulated ingestion of sodium fluorescein-containing antifreeze. Ann Emerg Med 2001; 38:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/25\">",
"      Sharma AN, O'Shaughnessy PM, Hoffman RS. Urine fluorescence: is it a good test for ethylene glycol ingestion? Pediatrics 2002; 109:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/26\">",
"      Koga Y, Purssell RA, Lynd LD. The irrationality of the present use of the osmole gap: applicable physical chemistry principles and recommendations to improve the validity of current practices. Toxicol Rev 2004; 23:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/27\">",
"      Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol 1993; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/28\">",
"      Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol 2002; 40:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/29\">",
"      Lynd LD, Richardson KJ, Purssell RA, et al. An evaluation of the osmole gap as a screening test for toxic alcohol poisoning. BMC Emerg Med 2008; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/30\">",
"      Steinhart B. Case report: severe ethylene glycol intoxication with normal osmolal gap--\"a chilling thought\". J Emerg Med 1990; 8:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/31\">",
"      Ammar KA, Heckerling PS. Ethylene glycol poisoning with a normal anion gap caused by concurrent ethanol ingestion: importance of the osmolal gap. Am J Kidney Dis 1996; 27:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/32\">",
"      Purssell RA, Lynd LD, Koga Y. The use of the osmole gap as a screening test for the presence of exogenous substances. Toxicol Rev 2004; 23:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/33\">",
"      Purssell RA, Pudek M, Brubacher J, Abu-Laban RB. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. Ann Emerg Med 2001; 38:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/34\">",
"      Sivilotti ML. Methanol intoxication. Ann Emerg Med 2000; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/35\">",
"      Kostic MA, Dart RC. Rethinking the toxic methanol level. J Toxicol Clin Toxicol 2003; 41:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/36\">",
"      Porter WH, Rutter PW, Bush BA, et al. Ethylene glycol toxicity: the role of serum glycolic acid in hemodialysis. J Toxicol Clin Toxicol 2001; 39:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/37\">",
"      De Leacy EA, Moxon LN, Ellis VM, et al. A report of accidental ethylene glycol ingestion in 2 siblings. Pathology 1995; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/38\">",
"      Baud FJ, Galliot M, Astier A, et al. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1988; 319:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/39\">",
"      Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999; 340:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/40\">",
"      Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001; 344:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/41\">",
"      Shannon M. Toxicology reviews: fomepizole--a new antidote. Pediatr Emerg Care 1998; 14:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/42\">",
"      Battistella M. Fomepizole as an antidote for ethylene glycol poisoning. Ann Pharmacother 2002; 36:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/43\">",
"      Sivilotti ML. Ethanol: tastes great! Fomepizole: less filling! Ann Emerg Med 2009; 53:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/44\">",
"      Dart RC, Borron SW, Caravati EM, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med 2009; 54:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/45\">",
"      Lepik KJ, Levy AR, Sobolev BG, et al. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole. Ann Emerg Med 2009; 53:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/46\">",
"      Boyer EW, Mejia M, Woolf A, Shannon M. Severe ethylene glycol ingestion treated without hemodialysis. Pediatrics 2001; 107:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/47\">",
"      Paasma R, Hovda KE, Tikkerberi A, Jacobsen D. Methanol mass poisoning in Estonia: outbreak in 154 patients. Clin Toxicol (Phila) 2007; 45:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/48\">",
"      Naraqi S, Dethlefs RF, Slobodniuk RA, Sairere JS. An outbreak of acute methyl alcohol intoxication. Aust N Z J Med 1979; 9:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/49\">",
"      Burns MJ, Graudins A, Aaron CK, et al. Treatment of methanol poisoning with intravenous 4-methylpyrazole. Ann Emerg Med 1997; 30:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/50\">",
"      Bekka R, Borron SW, Astier A, et al. Treatment of methanol and isopropanol poisoning with intravenous fomepizole. J Toxicol Clin Toxicol 2001; 39:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/51\">",
"      Youssef GM, Hirsch DJ. Validation of a method to predict required dialysis time for cases of methanol and ethylene glycol poisoning. Am J Kidney Dis 2005; 46:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/52\">",
"      McMurray M, Carty D, Toffelmire EB. Predicting methanol clearance during hemodialysis when direct measurement is not available. CANNT J 2002; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/53\">",
"      Burns AB, Bailie GR, Eisele G, et al. Use of pharmacokinetics to determine the duration of dialysis in management of methanol poisoning. Am J Emerg Med 1998; 16:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/54\">",
"      Chow MT, Di Silvestro VA, Yung CY, et al. Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate. Am J Kidney Dis 1997; 30:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/55\">",
"      Dorval M, Pichette V, Cardinal J, et al. The use of an ethanol- and phosphate-enriched dialysate to maintain stable serum ethanol levels during haemodialysis for methanol intoxication. Nephrol Dial Transplant 1999; 14:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/56\">",
"      Ghosh A, Boyd R. Leucovorin (calcium folinate) in \"antifreeze\" poisoning. Emerg Med J 2003; 20:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/57\">",
"      McMartin KE, Martin-Amat G, Makar AB, Tephly TR. Methanol poisoning. V. Role of formate metabolism in the monkey. J Pharmacol Exp Ther 1977; 201:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/58\">",
"      Hantson P, Vanormelingen P, Lecomte C, et al. Fatal methanol poisoning and organ donation: experience with seven cases in a single center. Transplant Proc 2000; 32:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/59\">",
"      L&oacute;pez-Navidad A, Caballero F, Gonz&aacute;lez-Segura C, et al. Short- and long-term success of organs transplanted from acute methanol poisoned donors. Clin Transplant 2002; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/60\">",
"      Caravati EM, Erdman AR, Christianson G, et al. Ethylene glycol exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/61\">",
"      Woolf AD, Wynshaw-Boris A, Rinaldo P, Levy HL. Intentional infantile ethylene glycol poisoning presenting as an inherited metabolic disorder. J Pediatr 1992; 120:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/3/4154/abstract/62\">",
"      Shoemaker JD, Lynch RE, Hoffmann JW, Sly WS. Misidentification of propionic acid as ethylene glycol in a patient with methylmalonic acidemia. J Pediatr 1992; 120:417.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 336 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4154=[""].join("\n");
var outline_f4_3_4154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Basic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Additional tests with toxic alcohol exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pitfalls in laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Testing for methanol and ethylene glycol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lactate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Urine testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Plasma osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview of emergent management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Airway, breathing, circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment with sodium bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Alcohol dehydrogenase inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Approach and initiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fomepizole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ethanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cofactor therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Preterminal care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Younger children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10832275\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/336|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/22/6509\" title=\"figure 1\">",
"      Methanol metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/7/8318\" title=\"figure 2\">",
"      Ethylene glycol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/336|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10561\" title=\"picture 1A\">",
"      Ca oxalate monohydrate crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42302\" title=\"picture 1B\">",
"      Calcium oxalate crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/3/8253\" title=\"table 1\">",
"      Methanol and ethylene glycol intoxication - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/0/38924\" title=\"table 2\">",
"      Causes of metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/9/18587\" title=\"table 3\">",
"      Differential dx of osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/60/12235\" title=\"table 4\">",
"      Indications for fomepizole or ethanol therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=related_link\" title=\"calculator 1\">",
"      Calculator: Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=related_link\" title=\"calculator 2\">",
"      Calculator: Serum osmolal gap (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9642?source=related_link\">",
"      Acute hemodialysis prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6613?source=related_link\">",
"      Alcoholic and fasting ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20423?source=related_link\">",
"      Isopropyl alcohol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_3_4155="Quick sources of sugar PI";
var content_f4_3_4155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Quick sources of sugar to treat low blood sugar",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        3 or 4 glucose tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &frac12; cup of juice or regular soda (not sugar-free)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 tablespoons of raisins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 or 5 saltine crackers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of sugar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 tablespoon of honey or corn syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 8 hard candies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These sources of sugar act quickly to treat low blood sugar levels. People with diabetes who use insulin or certain other diabetes medicines should carry at least one of these items at all times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4155=[""].join("\n");
var outline_f4_3_4155=null;
var title_f4_3_4156="Nasal vs oronasal masks";
var content_f4_3_4156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nasal versus oronasal masks: Advantages and disadvantages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variables",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nasal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oronasal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comfort",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Claustrophobia",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rebreathing",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lowers CO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permits expectoration*",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permits speech",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permits eating",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Function if nose obstructed",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: possible; ++: most likely; -: not possible.",
"     <br>",
"      *&nbsp;Expectoration is possible but requires the assistance of a respiratory therapist with oronasal mask.",
"      <br>",
"       &bull; Speech is possible but may vary depending on the degree of respiratory failure.",
"       <br>",
"        &Delta; Eating necessitates oronasal mask removal and may be contraindicated in patients with severe respiratory failure.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003; 124:699. Copyright &copy; 2003 American College of Chest Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4156=[""].join("\n");
var outline_f4_3_4156=null;
var title_f4_3_4157="Quinolone MIC anaer myco";
var content_f4_3_4157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activity of quinolones against selected anaerobes and mycobacteria in vitro",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Organism",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Representative MIC",
"       <sub>",
"        90",
"       </sub>",
"       (range), mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Ciprofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Norfloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Levofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Moxifloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Gemifloxacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacteroides fragilis",
"      </td>",
"      <td>",
"       4-128",
"      </td>",
"      <td>",
"       &gt;128",
"      </td>",
"      <td>",
"       2-12.5",
"      </td>",
"      <td>",
"       4-6.25",
"      </td>",
"      <td>",
"       0.2-4",
"      </td>",
"      <td>",
"       0.5-4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacteroides spp",
"      </td>",
"      <td>",
"       1-32",
"      </td>",
"      <td>",
"       128",
"      </td>",
"      <td>",
"       2-32",
"      </td>",
"      <td>",
"       (0.5-64)",
"      </td>",
"      <td>",
"       1-16",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fusobacterium spp",
"      </td>",
"      <td>",
"       2-8",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       2-16",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0.12-0.5",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clostridium perfringens",
"      </td>",
"      <td>",
"       0.5-8",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       0.5-8",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       0.25-0.5",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clostridium difficile",
"      </td>",
"      <td>",
"       8-25",
"      </td>",
"      <td>",
"       128",
"      </td>",
"      <td>",
"       12.5- 16",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anaerobic gram-positive cocci",
"      </td>",
"      <td>",
"       2-6.25",
"      </td>",
"      <td>",
"       16-64",
"      </td>",
"      <td>",
"       2-8",
"      </td>",
"      <td>",
"       1-8",
"      </td>",
"      <td>",
"       0.25-1",
"      </td>",
"      <td>",
"       0.125-0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium tuberculosis",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       0.8-1.3",
"      </td>",
"      <td>",
"       0.5-1",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium avium complex",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       &ge;16",
"      </td>",
"      <td>",
"       10-100",
"      </td>",
"      <td>",
"       (1-8)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium fortuitum",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1-3.1",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium kansasii",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       1-3.1",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIC",
"     <sub>",
"      90",
"     </sub>",
"     : minimal inhibitory concentration for 90 percent of strains.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eliopoulos, GM, Eliopoulos, CT. Activity in vitro of the quinolones. In: Quinolone antimicrobial agents (2nd ed), Hooper, DC, Wolfson, JS (Eds), American Society for Microbiology, Washington, DC, 1993, p. 161, and Wolfson, JS, Hooper, DC, Clin Microbiol Rev 1989; 2:378. Perry, CM, Barman Balfour, JA, Lamb, HM. Drugs 1999; 58:683. Barman Balfour, JA, Wiseman, LR. Drugs 1999; 57:363. Blondeau, JM. J Antimicrob Chemother 1999; 43(SupplB):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4157=[""].join("\n");
var outline_f4_3_4157=null;
var title_f4_3_4158="Follicle devel follicular phase";
var content_f4_3_4158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Human follicle development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 323px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of human follicle development during the follicular phase of the menstrual cycle. There are two major events in this process: increased sensitivity of a maturing follicle; and selection of a single dominant follicle. In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above some threshold value; the concentrations then decrease, preventing more than one follicle from undergoing preovulatory development.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fauser, BC, Van Hevsdeau, AM, et al. Manipulation of human ovarian function: Physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4158=[""].join("\n");
var outline_f4_3_4158=null;
var title_f4_3_4159="Neonatal HSV neck vesicles";
var content_f4_3_4159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neck vesicles in neonate with herpes simplex virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The early, untreated skin lesions associated with neonatal herpes simplex virus (HSV) infection are characteristically clear vesicles on an erythematous base, often touching or \"kissing,\" or coalesced in groups of vesicles. Culture of the clear fluid aspirated or swabbed from the vesicles will readily grow HSV in 24 to 48 hours, and slides made from cells scraped from the base of the lesion will show HSV viral antigens by direct immunofluorescence assay (DFA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gail J Demmler-Harrison, MD, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_3_4159=[""].join("\n");
var outline_f4_3_4159=null;
